Original Article
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
N Engl J Med 2007; 357:2666-2676December 27, 2007
- Abstract
Background
In an open-label, randomized, phase 3 trial, we compared the efficacy and safety of paclitaxel with that of paclitaxel plus bevacizumab, a monoclonal antibody against vascular endothelial growth factor, as initial treatment for metastatic breast cancer.
Methods
We randomly assigned patients to receive 90 mg of paclitaxel per square meter of body-surface area on days 1, 8, and 15 every 4 weeks, either alone or with 10 mg of bevacizumab per kilogram of body weight on days 1 and 15. The primary end point was progression-free survival; overall survival was a secondary end point.
Results
From December 2001 through May 2004, a total of 722 patients were enrolled. Paclitaxel plus bevacizumab significantly prolonged progression-free survival as compared with paclitaxel alone (median, 11.8 vs. 5.9 months; hazard ratio for progression, 0.60; P<0.001) and increased the objective response rate (36.9% vs. 21.2%, P<0.001). The overall survival rate, however, was similar in the two groups (median, 26.7 vs. 25.2 months; hazard ratio, 0.88; P=0.16). Grade 3 or 4 hypertension (14.8% vs. 0.0%, P<0.001), proteinuria (3.6% vs. 0.0%, P<0.001), headache (2.2% vs. 0.0%, P=0.008), and cerebrovascular ischemia (1.9% vs. 0.0%, P=0.02) were more frequent in patients receiving paclitaxel plus bevacizumab. Infection was more common in patients receiving paclitaxel plus bevacizumab (9.3% vs. 2.9%, P<0.001), but febrile neutropenia was uncommon (<1% overall).
Conclusions
Initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab prolongs progression-free survival, but not overall survival, as compared with paclitaxel alone. (ClinicalTrials.gov number, NCT00028990.)
Media in This Article
Figure 1
Analyses of Toxic Effects and Efficacy.Figure 2
Survival Analyses.Article Activity
- Article
Laboratory and clinical evidence supports the central role of angiogenesis in the progression of breast cancer.1,2 Multiple angiogenic factors are commonly expressed by invasive breast cancers; the 121-amino-acid isoform of vascular endothelial growth factor (VEGF) predominates.3 VEGF stimulates endothelial proliferation and migration, inhibits endothelial apoptosis, induces proteinases that remodel the extracellular matrix, increases vascular permeability and vasodilatation, and inhibits antigen-presenting dendritic cells.4 Differences in function among the various VEGF isoforms are not well defined, though VEGF-C has a predominant role in lymphangiogenesis, whereas VEGF-A is more potent in inducing vasodilatation and pathologic angiogenesis.5,6
Bevacizumab (Avastin, Genentech) is a humanized monoclonal antibody directed against all isoforms of VEGF-A. In a phase 1 and phase 2 study that tested three different doses of bevacizumab monotherapy (3, 10, or 20 mg per kilogram of body weight every 2 weeks) in 75 patients with previously treated metastatic breast cancer, the objective response rate was 9.3%, and 17% of patients had a response or were stable at 22 weeks. The dose of 10 mg per kilogram was suggested for further trials.7 In a phase 3 trial, the addition of bevacizumab to capecitabine in patients previously treated with anthracyclines and taxanes significantly increased the objective response rate (9.1% vs. 19.8%, P=0.001) but not progression-free survival (4.2 vs. 4.9 months; hazard ratio for disease progression, 0.98) or overall survival (15.1 vs. 14.5 months).8 The present trial (E2100) compared paclitaxel alone with paclitaxel plus bevacizumab as initial therapy for patients with metastatic breast cancer.
Methods
Patient Eligibility
Patients with histologically or cytologically confirmed metastatic breast cancer were eligible if they had not received previous cytotoxic therapy for metastatic disease. Previous hormonal therapy for metastatic breast cancer or cytotoxic adjuvant chemotherapy was allowed. Patients who had received taxane-based adjuvant therapy were required to have had a disease-free interval of at least 12 months after completion of taxane therapy. Those with human epidermal growth factor receptor type 2 (HER2)–positive breast cancer (graded as 3+ according to immunohistochemical analysis or gene amplification by fluorescence in situ hybridization) were eligible only if they had received trastuzumab. Additional inclusion criteria included Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and adequate renal, hepatic, and hematologic function. The presence of measurable tumor was not required for inclusion in the trial.
Patients were excluded if they had a history of or radiographic evidence of central nervous system disease; imaging of the central nervous system was required as a screening test. Patients were also excluded if they had had another cancer except basal-cell carcinoma of the skin or in situ cervical cancer within the previous 5 years, major surgery within the previous 4 weeks, or other antitumor therapy within the previous 21 days, or if they currently had a nonhealing wound or fracture, an infection requiring parenteral antibiotics, or clinically significant cardiovascular disease. Patients were excluded if they were currently taking therapeutic anticoagulant agents, nonsteroidal antiinflammatory agents, or more than 325 mg of aspirin daily, but prophylactic low-dose anticoagulant agents were permitted. Concurrent administration of bisphosphonates was allowed.
Local institutional review boards approved the protocol. Written informed consent was required from each patient before screening.
Treatment Plan
All patients received 90 mg of paclitaxel per square meter of body-surface area on days 1, 8, and 15 of every 28-day cycle. The dose was transiently reduced to 65 mg per square meter if any of the following toxic effects occurred: 1000 to 1499 granulocytes per cubic millimeter, 75,000 to 99,999 platelets per cubic millimeter, aspartate transaminase more than 5 but not more than 10 times the upper limit of normal, or 1.6 to 2.5 mg of bilirubin per deciliter (27 to 43 μmol per liter). The dose was permanently reduced to 65 mg per square meter in cases of prolonged granulocytopenia, fever associated with granulocytopenia, bleeding associated with 40,000 or fewer platelets per cubic millimeter, and any platelet count of 20,000 or fewer per cubic millimeter. Paclitaxel was withheld in cases of grade 3 neuropathy and resumed at a reduced dose on resolution to grade 0 or 1. It was permanently discontinued for severe hypersensitivity reactions or for grade 3 or 4 neuropathy lasting more than 3 weeks or recurring after dose reduction.
Patients assigned to combined therapy received 10 mg of bevacizumab per kilogram intravenously on days 1 and 15. Initially, bevacizumab was infused for 90 minutes; subsequent infusions were reduced to 60 minutes and then to 30 minutes, as tolerated. Premedication was optional. Treatment was interrupted for proteinuria (urinary protein excretion, ≥2000 mg per 24 hours). Antihypertensive therapy was administered at the discretion of the investigator. Bevacizumab therapy was not withheld or discontinued for paclitaxel-related toxic effects.
The patients continued therapy until disease progression or prohibitive toxic effects occurred. Patients assigned to combination therapy who discontinued paclitaxel without disease progression (i.e., because of toxic effects or at the discretion of the patient or investigator) could continue bevacizumab monotherapy until disease progression or unacceptable toxic effects occurred. Patients assigned to paclitaxel monotherapy could not receive bevacizumab at any time.
Safety and Efficacy
Clinical status, liver function, and serum creatinine levels were assessed before each cycle. A complete blood count was obtained before each paclitaxel infusion. Dipstick urinalysis was performed before each bevacizumab infusion; a 24-hour urine sample was obtained for 1+ protein on dipstick testing. Toxic effects were graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC), version 2.0. Disease status was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST)9 at baseline and every 12 weeks until progression. Quality of life was assessed with the use of the Functional Assessment of Cancer Therapy–Breast (FACT-B) questionnaire at baseline, week 17, and week 33.
Role of the Sponsor
The E2100 trial was conducted under a corporate research and development agreement between Genentech and the National Cancer Institute. Genentech provided bevacizumab and partial funding but did not participate in the design of the study or data collection. Analysis was conducted by the ECOG. The lead author made the decision to publish and wrote the manuscript, which was reviewed by all authors and submitted to Genentech for comment. The authors vouch for the completeness and accuracy of the data.
Statistical Analysis
The primary end point was progression-free survival, defined as the time from randomization to disease progression or death from any cause. In patients with measurable disease, progression was determined by RECIST. In patients without measurable lesions, progression was defined as development of new lesions or “unequivocal progression” of existing lesions. Secondary end points included objective response rate, toxic effects, overall survival, and quality of life.
The study design required enrollment of 685 patients to give full information at 546 progression-free survival events. The design yielded an 85% power to detect a 33% improvement in median progression-free survival (from 6 months to 8 months). The trial included prespecified stopping rules based on toxic effects, a prespecified stopping rule based on evaluation of efficacy after 171 progression-free survival events (at 31% information), and two additional planned interim efficacy analyses, at 50% and 78% information. Stopping rules in favor of the alternative hypotheses were obtained by the one-sided Lan–DeMets error spending rate function corresponding to the O'Brien–Fleming boundary10 with a one-sided type I error of 2.7%; those in favor of the null hypothesis were based on repeated-confidence-intervals methods.11 With the futility stopping rules taken into account, the overall type I error was expected to be 2.5% or less. With the use of survival data through June 7, 2007, we report the final analysis of progression-free survival and overall survival.
Treatment assignments were determined with the use of permuted blocks within strata. Stratification factors included disease-free interval (≤24 months vs. ≤24 months), number of metastatic sites (<3 vs. ≥3), previous adjuvant chemotherapy (yes vs. no), and estrogen-receptor status (positive vs. negative vs. unknown). All eligible patients were included in the efficacy analysis according to their treatment assignment. The primary prespecified analysis for progression-free survival and overall survival was stratified with the use of the log-rank test according to previous adjuvant therapy and disease-free interval. All treated patients were included in the analyses of toxic effects (analyzed as treated), regardless of eligibility.
Time-to-event distributions were estimated by Kaplan–Meier analysis. Cox proportional-hazards methods, with data stratified according to previous adjuvant therapy and disease-free interval, were used to estimate hazard ratios and test for the significance of time-to-event variables. The proportionality assumption was tested by the method of Grambsch and Therneau.12 Both the objective response rate and toxic effects were compared with the use of Fisher's exact test. Change in quality of life was compared with the use of the Wilcoxon rank-sum test. A pattern-mixture model analysis for longitudinal data with nonignorable missing data was also conducted.13 All P values are two-sided; confidence intervals are at the 95% level.
Results
Patient Population
We randomly assigned 722 patients to treatment between December 2001 and May 2004. All 711 treated patients were evaluated for toxic effects (Figure 1AFigure 1
Analyses of Toxic Effects and Efficacy.). Forty-nine enrolled patients (6.8%) did not meet all the eligibility criteria and were excluded from efficacy analyses (Figure 1B). Six eligible patients assigned to paclitaxel and two assigned to combination therapy were not treated but are included in the efficacy analysis according to their assignment. The two groups of patients were similar at baseline with respect to demographic and tumor characteristics, except that more patients assigned to paclitaxel alone had either measurable disease or visceral involvement (Table 1Table 1
Demographic and Disease Characteristics of Eligible Patients.).Efficacy
There were 624 reported events, and paclitaxel plus bevacizumab significantly prolonged progression-free survival as compared with paclitaxel alone (median, 11.8 vs. 5.9 months; hazard ratio for disease progression, 0.60; P<0.001) (Figure 2AFigure 2
Survival Analyses.). A Cox regression model including treatment (P<0.001) and the interaction between treatment and time (P<0.001) showed that the effect of treatment declined with time. The addition of bevacizumab to paclitaxel significantly improved the objective response rate in all eligible patients (36.9% vs. 21.2%, P<0.001) and in the subgroup of patients with measurable disease at baseline (49.2% vs. 25.2%, P<0.001). At data cutoff, 483 patients had died, the majority (88.8%) from progressive disease. Combined therapy increased the 1-year survival rate (81.2% vs. 73.4%, P=0.01); however, the median overall survival was similar in the group receiving combined therapy and in the group receiving paclitaxel alone (26.7 months and 25.2 months, respectively; hazard ratio, 0.88; P=0.16) (Figure 2B).Proportional-hazards models stratified according to disease-free interval and adjuvant chemotherapy were fitted to investigate the effect of bevacizumab on progression-free survival in clinically relevant subgroups of patients (Figure 3Figure 3
Hazard Ratios for Disease Progression.). The hazard ratios favored combined therapy in all subgroups but did not reach statistical significance in some of the smaller subgroups. The addition of bevacizumab prolonged progression-free survival from 3.0 to 12.0 months (hazard ratio, 0.46; P<0.001) in patients who had received taxane-based adjuvant therapy. The effect of bevacizumab declined significantly with age treated as a continuous variable (P=0.04). There was no significant interaction between treatment and any other patient characteristic.Slightly more patients with visceral involvement or measurable disease were assigned to paclitaxel monotherapy than to combination therapy. To investigate the influence of this imbalance and other potential prognostic factors on our results, we conducted a multivariate analysis using the proportional-hazards model, with data stratified according to disease-free interval and adjuvant chemotherapy. We considered the following covariates: treatment assignment, measurable disease, number of disease sites, estrogen-receptor status, location of disease (visceral only vs. bone only), age (as a continuous variable), race (white vs. other), progesterone-receptor status, menopausal status, and the interactions between treatment assignment and age and time. The final model, which satisfied the Cox model assumption, included treatment assignment (P<0.001), measurable disease (P=0.03), number of disease sites (P=0.003), estrogen-receptor status (P<0.001), age (P=0.02), the interaction between treatment assignment and age (P=0.02), and the interaction between treatment assignment and time (P<0.001).
To investigate the influence of patient- or investigator-driven ascertainment bias, we compared the distribution of the interval from the last negative disease assessment with the time of documented progression. The median was 2.8 months in both groups (P=0.94 by the Wilcoxon two-sample test). Similarly, we found no difference in the proportion of patients with an interval less than 2.5 months (30.1% vs. 31.7%). Finally, we moved all progression-free survival times forward to the next scheduled assessment and recalculated progression-free survival. The results were similar to those of our original analysis (12.8 vs. 6.2 months; hazard ratio, 0.61; P<0.001).
Toxic Effects
The addition of bevacizumab had little effect on the frequency or severity of expected paclitaxel-related toxic effects (Table 2Table 2
Treatment-Related Toxic Effects.). Hematologic, gastrointestinal, and musculoskeletal toxic effects were minimal and similar in both groups. Grade 3 or 4 neuropathy (23.6% vs. 17.6%, P=0.03), infection (9.3% vs. 2.9%, P<0.001) and fatigue (8.5% vs. 4.9%, P=0.04) were more frequent in the combination group. Paclitaxel was discontinued at least 3 weeks before disease progression (or before the last disease assessment for patients without progression) in 117 patients treated with paclitaxel (35.9%) and 178 patients treated with paclitaxel plus bevacizumab (51.3%), most commonly because of cumulative toxic effects. The median duration of paclitaxel treatment was 5.1 months in patients treated with paclitaxel alone and 7.1 months in patients treated with combined therapy. Of the patients in the combination group, 74 (21.3%) continued bevacizumab monotherapy for a median of 3.7 months. The Supplementary Appendix (available with the full text of this article at www.nejm.org) lists the reasons for discontinuation of treatment in both groups.Hypertension was more common in patients receiving bevacizumab and was managed with medical therapy; grade 4 hypertension developed in only one patient, resulting in discontinuation of bevacizumab. Proteinuria was rarely clinically significant. Grade 3 hemorrhage was uncommon and its frequency did not differ between treatment groups; grade 4 hemorrhage was not reported. Thromboembolic events were infrequent overall, but there was a significant increase in cerebrovascular ischemia among patients receiving combined therapy (1.9% vs. 0.0%, P=0.02). Patients receiving combined therapy were also more likely to report grade 3 or 4 headaches (2.2% vs. 0.0%, P=0.008).
Quality of Life
The FACT-B questionnaire was completed by 631 patients at baseline, 488 at 17 weeks, and 368 at 33 weeks. There were no significant differences in the mean change in scores from baseline for the FACT-B, the FACT-B subscale, or the Trial Outcome Index14,15 (the sum of the physical well-being, functional well-being, and breast cancer–specific questions in the FACT-B) (Figure 4Figure 4
Changes in Quality-of-Life Measures.).Discussion
In this phase 3 trial of paclitaxel plus bevacizumab as the initial treatment of metastatic breast cancer, the safety profile of the combination was similar to profiles reported in previous randomized trials.8,16-18 Most toxic effects were minimal, rarely limited therapy, and did not have a detrimental effect on overall quality of life.15
We enrolled patients with predominantly HER2-negative breast cancer; no patient received concurrent trastuzumab. Further studies are needed to assess the efficacy of bevacizumab in patients with HER2-positive metastatic breast cancer.19,20 In our trial, bevacizumab was not given to patients who had a tumor with a specific molecular phenotype. Although benefit was seen across a number of clinically important subgroups, our results would be strengthened by the ability to identify patients most likely to benefit from VEGF-directed therapies.
In a previous phase 3 study, the addition of bevacizumab to capecitabine significantly increased the objective response rate but not progression-free survival or overall survival.8 What might account for the different results in these trials? It seems unlikely that chance could account for the improvement in progression-free survival found in our trial. Investigator or patient bias, always a consideration in open-label studies, is unlikely to explain our results. If such biases had a large role, we would have expected to see a greater improvement in patients with nonmeasurable lesions, where disease assessment is necessarily subjective. Actually, the hazard ratio was more favorable in patients with measurable disease than in those with nonmeasurable disease (0.55 vs. 0.68).
Substantial differences between the patient populations of these studies may account for the disparate results. All patients in the earlier study had received previous anthracycline and taxane therapy, and most (more than 85%) had received chemotherapy for metastatic disease.8 In contrast, 35.2% of our patients had not received any previous chemotherapy, and only 13.2% had received both an anthracycline and a taxane as adjuvant therapy.
A recent phase 2 trial found a median time to disease progression of only 5.7 months (95% confidence interval, 4.9 to 8.4) with capecitabine plus bevacizumab as initial chemotherapy.21 Perhaps paclitaxel is uniquely synergistic with bevacizumab. Indeed, the taxanes have distinct antiangiogenic activity.22 In preclinical studies, VEGF protected endothelial cells from the antiangiogenic properties of docetaxel; bevacizumab overcame this protective effect in vitro and in vivo.23
Despite a striking improvement in progression-free survival, the addition of bevacizumab did not prolong overall survival in this study. Patients with metastatic breast cancer frequently receive multiple therapies during the course of their disease. Data on treatment administered after progression were not collected in this trial, precluding an exploratory analysis of the influence of subsequent therapy on overall survival. Though the mechanisms of resistance to bevacizumab are not well defined,24,25 it is possible that resistance to bevacizumab results in relative resistance to subsequent therapies. Alternatively, rebound increases in VEGF on discontinuation of bevacizumab could result in more aggressive disease. Resistance to paclitaxel, whether mediated by increased expression of the multidrug resistance protein26 or by microtubule mutations,27 could also cause resistance to subsequent chemotherapy.
We found that treatment with bevacizumab early in the course of metastatic breast cancer, when angiogenic pathways are less redundant, improved progression-free survival and the objective response rate. Although our patients were receiving their first treatment for metastatic breast cancer, only a third had never received any chemotherapy. More than 80% had overt visceral involvement, presumably with an established vasculature. In short, first-line therapy for metastatic breast cancer is not “early” in the natural history of breast cancer. Recent laboratory studies suggest that the initial events in the development of metastasis are VEGF-dependent.28,29 If this is true, the most successful clinical application of angiogenesis inhibitors is likely to be in patients with micrometastatic disease in the adjuvant setting.
Supported in part by Public Health Service Grants CA23318, CA66636, CA21115, CA49883, and CA16116 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, and by Genentech.
The views expressed are those of the authors and do not necessarily represent the official views of the National Cancer Institute.
Dr. Miller reports receiving lecture fees and consulting fees for service on breast cancer advisory boards from Roche. Dr. Gralow reports receiving lecture fees and consulting fees for service on breast cancer advisory boards from Genentech and Roche. Dr. Dickler and Dr. Cobleigh report receiving consulting fees from Genentech for service on breast cancer advisory boards. Dr. Cobleigh reports receiving lecture fees from Genentech. Dr. Perez reports receiving consulting fees from Genentech, GlaxoSmithKline, Bristol-Myers Squibb, and Sanofi-Aventis for service on breast cancer advisory boards, as well as grant support for clinical translational studies from Genentech. No other potential conflict of interest relevant to this article was reported.
We thank Dr. George Sledge and Dr. Robert Gray for helpful discussions and Carol Chami for providing technical assistance in preparing the manuscript.
Source Information
From Indiana University Cancer Center, Indianapolis (K.M.); Dana–Farber Cancer Institute, Boston (M.W.); Puget Sound Oncology Consortium, Seattle (J.G.); Memorial Sloan-Kettering Cancer Center, New York (M.D.); Rush–Presbyterian–St. Luke's Medical Center, Chicago (M.C.); Mayo Clinic, Jacksonville, FL (E.A.P.); British Columbia Cancer Agency–Vancouver Cancer Center, Vancouver, BC, Canada (T.S.); Evanston Northwestern Healthcare and Robert H. Lurie Comprehensive Cancer Center of Northwestern University — both in Evanston, IL (D.C.); and Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore (N.E.D.).
Address reprint requests to Dr. Miller at the Indiana Cancer Pavilion, 535 Barnhill Dr., RT473, Indianapolis, IN 46202, or at kathmill@iupui.edu.
- References
References
1
Folkman J . What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6
CrossRef | Web of Science | Medline2
Gasparini G. Angiogenesis in breast cancer: role in biology, tumor progression, and prognosis. In: Bowcock A, ed. Breast cancer: molecular genetics, pathogenesis, and therapeutics. Totowa, NJ: Humana Press, 1999:347-71.
3
Relf M ,LeJeune S ,Scott PA , et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963-969
Web of Science | Medline4
Ferrara N ,Davis-Smyth T . The biology of vascular endothelial growth factor. Endocrinol Rev 1997;18:4-25
CrossRef | Web of Science | Medline5
Dvorak HF . Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-4380
CrossRef | Web of Science | Medline6
Ferrara N ,Gerber HP ,LeCouter J . The biology of VEGF and its receptors. Nat Med 2003;9:669-676
CrossRef | Web of Science | Medline7
Cobleigh M ,Miller K ,Langmuir V , et al. Phase II dose escalation trial of Avastin (bevacizumab) in women with previously treated metastatic breast cancer. Breast Cancer Res Treat 2001;69:301-301
Web of Science8
Miller KD ,Chap LI ,Holmes FA , et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-799
CrossRef | Web of Science | Medline9
Therasse P ,Arbuck SG ,Eisenhauer EA , et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216
CrossRef | Web of Science | Medline10
O'Brien PC ,Fleming T . A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556
CrossRef | Web of Science | Medline11
Jennison C ,Turnbull B . Interim analyses: the repeated confidence interval approach. J R Stat Soc [B] 1989;51:305-36112
Grambsch P ,Therneau T . Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-526
CrossRef | Web of Science13
Fitzmaurice GM ,Laird NM ,Shneyer L . An alternative parameterization of the general linear mixture model for longitudinal data with non-ignorable drop-outs. Stat Med 2001;20:1009-1021
CrossRef | Web of Science | Medline14
Brady MJ ,Cella DF ,Mo F , et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 1997;15:974-986
Web of Science | Medline15
Wagner L ,Wang M ,Miller K , et al. Health-related quality of life among patients with metastatic breast cancer receiving paclitaxel versus paclitaxel plus bevacizumab: results from the Eastern Cooperative Oncology Group (ECOG) study E2100. Breast Cancer Res Treat 2006;100:Suppl 1:S239-S239
CrossRef | Web of Science16
Hurwitz H ,Fehrenbacher L ,Novotny W , et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342
Full Text | Web of Science | Medline17
Sandler A ,Gray R ,Perry MC , et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550[Erratum, N Engl J Med 2007;356:318.]
Full Text | Web of Science | Medline18
Skillings JR ,Johnson D ,Miller K , et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. J Clin Oncol 2005;23:Suppl:196S-196S
Web of Science19
Pegram MD ,Reese DM . Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin Oncol 2002;29:Suppl 11:29-37
Web of Science | Medline20
Pegram M ,Chan D ,Dichmann RA , et al. Phase II combined biological therapy targeting HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. Breast Cancer Res Treat 2006;100:Suppl 1:S28-S28
Web of Science21
Sledge G ,Miller K ,Moisa CG ,Gradishar W . Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer (XCALIBr Trial). J Clin Oncol 2007;25:Suppl:18S-18S22
Miller KD ,Sweeney CJ ,Sledge GW Jr . Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001;19:1195-1206
Web of Science | Medline23
Sweeney CJ ,Miller KD ,Sissons SE , et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61:3369-3372
Web of Science | Medline24
Kerbel RS ,Yu J ,Tran J , et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001;20:79-86
CrossRef | Web of Science | Medline25
Miller KD ,Sweeney CJ ,Sledge GW Jr . The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era. Ann Oncol 2003;14:20-28
CrossRef | Web of Science | Medline26
Brouty-Boye D ,Kolonias D ,Wu CJ ,Savaraj N ,Lampidis TJ . Relationship of multidrug resistance to rhodamine-123 selectivity between carcinoma and normal epithelial cells: taxol and vinblastine modulate drug efflux. Cancer Res 1995;55:1633-1638
Web of Science | Medline27
Hari M ,Loganzo F ,Annable T , et al. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. Mol Cancer Ther 2006;5:270-278
CrossRef | Web of Science | Medline28
Kaplan RN ,Riba RD ,Zacharoulis S , et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820-827
CrossRef | Web of Science | Medline29
Steeg PS . Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006;12:895-904
CrossRef | Web of Science | Medline
- Citing Articles (662)
Citing Articles
1
Jean-Philippe Jacquin, Cyrus Chargari, Julie Thorin, Dominique Mille, Adrien Mélis, Hubert Orfeuvre, Guillaume Clavreul, Loic Chaigneau, Alice Nourissat, Chantal Dumanoir, Jacqueline Savary, Yacine Merrouche, Nicolas Magné. (2012) Phase II Trial of Pegylated Liposomal Doxorubicin in Combination With Gemcitabine in Metastatic Breast Cancer Patients. American Journal of Clinical Oncology 35:1, 18-21
CrossRef2
Erin R. Gardner, Martha Kelly, Eric Springman, Kyoung-jin Lee, Haiqing Li, William Moore, William D. Figg. (2012) Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab. Investigational New Drugs 30:1, 90-97
CrossRef3
Richard M. Steingart, George L. Bakris, Helen X. Chen, Ming-Hui Chen, Thomas Force, S. Percy Ivy, Carl V. Leier, Glenn Liu, Daniel Lenihan, JoAnn Lindenfeld, Michael L. Maitland, Scot C. Remick, W.H. Wilson Tang. (2012) Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. American Heart Journal 163:2, 156-163
CrossRef4
Ahmad Awada, Ivana Bozovic-Spasojevic, Louis Chow. (2012) New therapies in HER2-positive breast cancer: A major step towards a cure of the disease?. Cancer Treatment Reviews
CrossRef5
Shengyan Hong, Li Shi. (2012) Predictive power to assist phase 3 go/no go decision based on phase 2 data on a different endpoint. Statistics in Medicinen/a-n/a
CrossRef6
Laura Horsley, Kalena Marti, GC Jayson. (2012) Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy. Expert Opinion on Drug Metabolism & Toxicology1-11
CrossRef7
von Minckwitz, Gunter, Eidtmann, Holger, Rezai, Mahdi, Fasching, Peter A., Tesch, Hans, Eggemann, Holm, Schrader, Iris, Kittel, Kornelia, Hanusch, Claus, Kreienberg, Rolf, Solbach, Christine, Gerber, Bernd, Jackisch, Christian, Kunz, Georg, Blohmer, Jens-Uwe, Huober, Jens, Hauschild, Maik, Fehm, Tanja, Müller, Berit Maria, Denkert, Carsten, Loibl, Sibylle, Nekljudova, Valentina, Untch, Michael, . (2012) Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer. New England Journal of Medicine 366:4, 299-309
Full Text8
Bear, Harry D., Tang, Gong, Rastogi, Priya, Geyer, Charles E. Jr., Robidoux, André, Atkins, James N., Baez-Diaz, Luis, Brufsky, Adam M., Mehta, Rita S., Fehrenbacher, Louis, Young, James A., Senecal, Francis M., Gaur, Rakesh, Margolese, Richard G., Adams, Paul T., Gross, Howard M., Costantino, Joseph P., Swain, Sandra M., Mamounas, Eleftherios P., Wolmark, Norman, . (2012) Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer. New England Journal of Medicine 366:4, 310-320
Full Text9
Montero, Alberto J., Vogel, Charles, . (2012) Fighting Fire with Fire: Rekindling the Bevacizumab Debate. New England Journal of Medicine 366:4, 374-375
Full Text10
Else Maae, Dorte Aalund Olsen, Karina Dahl Steffensen, Erik Hugger Jakobsen, Ivan Brandslund, Flemming Brandt Sørensen, Anders Jakobsen. (2012) Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer. Breast Cancer Research and Treatment
CrossRef11
Filipa Lynce, Sandra M Swain. (2012) Avastin withdrawal symptoms. Expert Opinion on Pharmacotherapy293-298
CrossRef12
Mary Cianfrocca. (2012) What Are the Most Important New Targets in Breast Cancer?. Current Breast Cancer Reports
CrossRef13
Andrew S. Roberts, Michael J. Campa, Elizabeth B. Gottlin, Chen Jiang, Kouros Owzar, Hedy L. Kindler, Alan P. Venook, Richard M. Goldberg, Eileen M. O'Reilly, Edward F. Patz. (2012) Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). Cancer 118:2, 571-578
CrossRef14
Jennifer Glendenning, Sheeba Irshad, Andrew Tutt. (2012) Treatment of Metastatic Triple-Negative Breast Cancer. Current Breast Cancer Reports
CrossRef15
Sean Warsch, Alberto J. Montero, Stefan Glück. (2012) Novel Cytotoxic Agents in the Treatment of Metastatic Breast Cancer. Current Breast Cancer Reports
CrossRef16
Astrid A.M. Van der Veldt, Mark Lubberink, Idris Bahce, Maudy Walraven, Michiel P. de Boer, Henri N.J.M. Greuter, N. Harry Hendrikse, Jonas Eriksson, Albert D. Windhorst, Pieter E. Postmus, Henk M. Verheul, Erik H. Serné, Adriaan A. Lammertsma, Egbert F. Smit. (2012) Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs. Cancer Cell 21:1, 82-91
CrossRef17
S A Holstein, R J Hohl. (2012) Therapeutic Additions and Possible Deletions in Oncology in 2011. Clinical Pharmacology & Therapeutics 91:1, 15-17
CrossRef18
Alain Lortholary, Anne-Claire Hardy-Bessard, Thomas Bachelot, Gaëtan Rauglaudre, Jérôme Alexandre, Hugues Bourgeois, Dominique Jaubert, Désiré Paraiso, Rémy Largillier. (2012) A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer. Breast Cancer Research and Treatment 131:1, 127-135
CrossRef19
Yanelys Morera, Mónica Bequet-Romero, Marta Ayala, Pedro Puente Pérez, Jorge Castro, Javier Sánchez, José Suárez Alba, Julio Ancízar, Karelia Cosme, Jorge V. Gavilondo. (2012) Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates. Vaccine 30:2, 368-377
CrossRef20
Melanie M. Badtke, Purevsuren Jambal, Wendy W. Dye, Monique A. Spillman, Miriam D. Post, Kathryn B. Horwitz, Britta M. Jacobsen. (2012) Unliganded progesterone receptors attenuate taxane-induced breast cancer cell death by modulating the spindle assembly checkpoint. Breast Cancer Research and Treatment 131:1, 75-87
CrossRef21
Ruchi Saxena, Anila Dwivedi. (2012) ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective. Medicinal Research Reviews 32:1, 166-215
CrossRef22
Rodrigo Dienstmann, Felipe Ades, Kamal S. Saini, Otto Metzger-Filho. (2012) Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer. Drug Safety 35:1, 15-25
CrossRef23
François Goldwasser. (2012) Traitement du cancer colorectal métastatique : une illustration de l’évolution des concepts fondateurs de la cancérologie. La Presse Médicale 41:1, 46-50
CrossRef24
Caroline Hilmi, Mélanie Guyot, Gilles Pagès. (2012) VEGF Spliced Variants: Possible Role of Anti-Angiogenesis Therapy. Journal of Nucleic Acids 2012, 1-7
CrossRef25
David Miles, Christoph Zielinski, Miguel Martin, Eduard Vrdoljak, Nicholas Robert. (2012) Combining capecitabine and bevacizumab in metastatic breast cancer: A comprehensive review. European Journal of Cancer
CrossRef26
Paolo Carli, Elisa Turchet, Daniela Quitadamo, Antonella Spada, Gianmaria Miolo, Elda Lamaj, Simon Spazzapan, Vincenzo Di Lauro, Riccardo Dolcetti, Andrea Veronesi, Diana Crivellari. (2012) Target therapy in elderly breast cancer patients. Critical Reviews in Oncology/Hematology
CrossRef27
L. Biganzoli, E. Di Vincenzo, Z. Jiang, M. Lichinitser, Z. Shen, R. Delva, N. Bogdanova, G. L. Vivanco, Z. Chen, Y. Cheng, M. Just, M. Espie, J. Vinholes, C. Hamm, D. Crivellari, E. Chmielowska, V. Semiglazov, F. Dalenc, I. Smith. (2012) First-line bevacizumab-containing therapy for breast cancer: results in patients aged >=70 years treated in the ATHENA study. Annals of Oncology 23:1, 111-118
CrossRef28
, Laurence Legros, Bohrane Slama, Jean-Michel Karsenti, Norbert Vey, Shanti Natarajan-Amé, Eric Watel, Bruno Richard, Krimo Bouabdallah, Lionel Mannone, Maxime Benchetrit, Irit Touitou, Sébastien Huault, Jérome Durivault, Damien Ambroseti, Anne-Odile Hueber, Pierre Fenaux, Francois Dreyfus. (2012) Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level. Annals of Hematology 91:1, 39-46
CrossRef29
Monica Fornier, Pierre Fumoleau. (2012) The Paradox of Triple Negative Breast Cancer: Novel Approaches to Treatment. The Breast Journal 18:1, 41-51
CrossRef30
Andrew Gaya, Vivien Tse. (2012) A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treatment Reviews
CrossRef31
Keith D. Amos, Barbara Adamo, Carey K. Anders. (2012) Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials. International Journal of Breast Cancer 2012, 1-7
CrossRef32
Phuong Khanh Morrow, Rashmi K. Murthy, Joe D. Ensor, Gilad S. Gordon, Kim A. Margolin, Anthony D. Elias, Walter J. Urba, David E. Weng, Hope S. Rugo, Gabriel N. Hortobagyi. (2012) An open-label, phase 2 trial of RPI.4610 (angiozyme) in the treatment of metastatic breast cancer. Cancern/a-n/a
CrossRef33
Kosuke Akiyama, Noritaka Ohga, Yasuhiro Hida, Taisuke Kawamoto, Yoshihiro Sadamoto, Shuhei Ishikawa, Nako Maishi, Tomoshige Akino, Miyako Kondoh, Aya Matsuda, Nobuo Inoue, Masanobu Shindoh, Kyoko Hida. (2012) Tumor Endothelial Cells Acquire Drug Resistance by MDR1 Up-Regulation via VEGF Signaling in Tumor Microenvironment. The American Journal of Pathology
CrossRef34
B. Ramaswamy, W. Fiskus, B. Cohen, C. Pellegrino, D. L. Hershman, E. Chuang, Thehang Luu, G. Somlo, M. Goetz, R. Swaby, C. L. Shapiro, V. Stearns, P. Christos, I. Espinoza-Delgado, K. Bhalla, J. A. Sparano. (2011) Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. Breast Cancer Research and Treatment
CrossRef35
Rachel A. Freedman, Carey K. Anders. (2011) Treatment of Breast Cancer Brain Metastases. Current Breast Cancer Reports
CrossRef36
Rosa Lerose, Pellegrino Musto, Michele Aieta, Carla Papa, Alfredo Tartarone. (2011) Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience. European Journal of Clinical Pharmacology
CrossRef37
Manish R. Sharma, Richard L. Schilsky. (2011) Role of randomized phase III trials in an era of effective targeted therapies. Nature Reviews Clinical Oncology
CrossRef38
M. N. Fornier, P. G. Morris, A. Abbruzzi, G. D'Andrea, T. Gilewski, J. Bromberg, C. Dang, M. Dickler, S. Modi, A. D. Seidman, N. Sklarin, J. Chang, L. Norton, C. A. Hudis. (2011) A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Annals of Oncology 22:12, 2575-2581
CrossRef39
John G. Elvin, Ruairidh G. Couston, Christopher F. van der Walle. (2011) Therapeutic antibodies: Market considerations, disease targets and bioprocessing. International Journal of Pharmaceutics
CrossRef40
Edouard Lecarpentier, Lamia Ouaffi, Olivier Mir, Paul Berveiller, Melinda Maurel, Eric Pujade-Lauraine, Jean Luc Bouillot, Nicolas Veyrie. (2011) Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases. Investigational New Drugs 29:6, 1500-1503
CrossRef41
David Cella, Molin Wang, Lynne Wagner, Kathy Miller. (2011) Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100). Breast Cancer Research and Treatment 130:3, 855-861
CrossRef42
Lee S. Schwartzberg, Francis P. Arena, David M. Mintzer, Amanda L. Epperson, Mark S. Walker. (2011) Phase II Multicenter Trial of Albumin-Bound Paclitaxel and Capecitabine in First-Line Treatment of Patients With Metastatic Breast Cancer. Clinical Breast Cancer
CrossRef43
R. -J. Bensadoun, J. -P. Durand, M. Palma, F. Scotté, D. Mayeur. (2011) Prise en charge préventive et curative des mucites du tractus digestif (mucites buccopharyngées, œsogastro-intestinales et anorectales). Oncologie 13:12, 825-832
CrossRef44
Larry D. Sasich, Sana Rikabi Sukkari. (2011) The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab). Saudi Pharmaceutical Journal
CrossRef45
John Pippen, Devchand Paul, Svetislava Vukelja, Alicia Clawson, Jose Iglesias. (2011) Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer. Breast Cancer Research and Treatment 130:3, 825-831
CrossRef46
Javier Cortés, Mireia Caralt, Suzette Delaloge, Hernan Cortes-Funes, Jean-Yves Pierga, Kathleen I. Pritchard, David T. Bollag, David W. Miles. (2011) Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. European Journal of Cancer
CrossRef47
Nagi S. El Saghir, Arafat Tfayli, Hassan A. Hatoum, Zahi Nachef, Phuong Dinh, Ahmad Awada. (2011) Treatment of metastatic breast cancer: State-of-the-art, subtypes and perspectives. Critical Reviews in Oncology/Hematology 80:3, 433-449
CrossRef48
Sara Mariucci, Bianca Rovati, Mariangela Manzoni, Matteo Giovanni Della Porta, Giuditta Comolli, Sara Delfanti, Marco Danova. (2011) Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors. Clinical and Experimental Medicine 11:4, 199-210
CrossRef49
M. Ghosn, P. Aftimos, F. S. Farhat, J. G. Kattan, C. Hanna, N. Haddad, F. Nasr, G. Chahine. (2011) A phase II randomized study comparing navelbine and capecitabine (Navcap) followed either by Navcap or by weekly docetaxel in the first-line treatment of HER-2/neu negative metastatic breast cancer. Medical Oncology 28:S1, 142-151
CrossRef50
Ellen B. Kossoff, Nuttapong Ngamphaiboon, Thomas J. Laudico, Tracey L. O’Connor. (2011) Weekly ixabepilone administration in heavily pretreated metastatic breast cancer patients. Medical Oncology 28:S1, 115-120
CrossRef51
Christos Vaklavas, Andres Forero-Torres. (2011) How do I Treat “Triple-Negative” Disease. Current Treatment Options in Oncology 12:4, 369-388
CrossRef52
Pilar Eroles, Ana Bosch, J. Alejandro Pérez-Fidalgo, Ana Lluch. (2011) Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treatment Reviews
CrossRef53
Ryo Morita, Kazuhiro Sato, Mariko Nakano, Hajime Miura, Hidesato Odaka, Kiyoshi Nobori, Toshimitsu Kosaka, Masaaki Sano, Hiroyuki Watanabe, Takanobu Shioya, Hiroshi Ito. (2011) Endothelial progenitor cells are associated with response to chemotherapy in human non-small-cell lung cancer. Journal of Cancer Research and Clinical Oncology 137:12, 1849-1857
CrossRef54
T. Schmidt, P. Carmeliet. (2011) Angiogenesis: A Target in Solid Tumors, Also in Leukemia?. Hematology 2011:1, 1-8
CrossRef55
Takashi Oshima, Munetaka Masuda. (2011) Molecular targeted agents for gastric and gastroesophageal junction cancer. Surgery Today
CrossRef56
Carlos L. Arteaga, Mark X. Sliwkowski, C. Kent Osborne, Edith A. Perez, Fabio Puglisi, Luca Gianni. (2011) Treatment of HER2-positive breast cancer: current status and future perspectives. Nature Reviews Clinical Oncology 9:1, 16-32
CrossRef57
Javier Cortes, Maria Vidal. (2011) Beyond taxanes: the next generation of microtubule-targeting agents. Breast Cancer Research and Treatment
CrossRef58
N. Emami-Shahri, T. Hagemann. (2011) Resistance--the true face of biological defiance. Rheumatology
CrossRef59
Thomas Resch, Andreas Pircher, Christian M. Kähler, Johann Pratschke, Wolfgang Hilbe. (2011) Endothelial Progenitor Cells: Current Issues on Characterization and Challenging Clinical Applications. Stem Cell Reviews and Reports
CrossRef60
Michael J. Berger, Leslie J. Dunlea, Amy E. Rettig, Maryam B. Lustberg, Gary S. Phillips, Charles L. Shapiro. (2011) Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Supportive Care in Cancer
CrossRef61
Chao Cao, Jianmiao Wang, Hansvin Bunjhoo, Yongjian Xu, Huijuan Fang. (2011) Risk profile of bevacizumab in patients with non-small cell lung cancer: A meta-analysis of randomized controlled trials. Acta Oncologica1-6
CrossRef62
Veronique Lorgis, Geric Maura, Guillaume Coppa, Kahina Hassani, Luc Taillandier, Bruno Chauffert, Lionel Apetoh, Sylvain Ladoire, François Ghiringhelli. (2011) Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts. Journal of Neuro-Oncology
CrossRef63
Kyung-Jae Park, Hideyuki Kano, Aditya Iyer, Xiaomin Liu, Ajay Niranjan, John C. Flickinger, Frank S. Lieberman, L. Dade Lunsford, Douglas Kondziolka. (2011) Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case–control study. Journal of Neuro-Oncology
CrossRef64
Ciprian Chira, Julian Jacob, Najib Derhem, Marc A. Bollet, François Campana, Virginie Marchand, Jean-Yves Pierga, Alain Fourquet, Youlia M. Kirova. (2011) Preliminary experience of whole-brain radiation therapy (WBRT) in breast cancer patients with brain metastases previously treated with bevacizumab-based chemotherapy. Journal of Neuro-Oncology 105:2, 401-408
CrossRef65
W. Jacot, G. Romieu, P.-J. Lamy. (2011) Cancer du sein métastatique : progrès dans la prise en charge et limites actuelles. Imagerie de la Femme
CrossRef66
M. H. G. Langenberg, P. O. Witteveen, J. Roodhart, M. P. Lolkema, H. M. W. Verheul, M. Mergui-Roelvink, E. Brendel, J. Kratzschmar, B. Loembe, A. Nol-Boekel, O. Christensen, J. H. M. Schellens, E. E. Voest. (2011) Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. Annals of Oncology 22:11, 2508-2515
CrossRef67
Gaetana Di Fede, Giuseppe Bronte, Sergio Rizzo, Christian Rolfo Cervetto, Gianfranco Cocorullo, Gaspare Gulotta, Viviana Bazan, Antonio Russo. (2011) Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors. Expert Opinion on Biological Therapy 11:11, 1433-1445
CrossRef68
Min S. Park, Shreyaskumar R. Patel, Joseph A. Ludwig, Jonathan C. Trent, Charles A. Conrad, Alexander J. Lazar, Wei-Lien Wang, Piyaporn Boonsirikamchai, Haesun Choi, Xuemei Wang, Robert S. Benjamin, Dejka M. Araujo. (2011) Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer 117:21, 4939-4947
CrossRef69
Sarah Barton, Charles Swanton. (2011) Recent Developments in Treatment Stratification for Metastatic Breast Cancer. Drugs 71:16, 2099-2113
CrossRef70
Filippo Bellati, Chiara Napoletano, Maria Luisa Gasparri, Ilary Ruscito, Claudia Marchetti, Sandro Pignata, Federica Tomao, Pierluigi Benedetti Panici, Marianna Nuti. (2011) Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms. Critical Reviews in Oncology/Hematology
CrossRef71
Theodoros Foukakis, Tommy Fornander, Tobias Lekberg, Henrik Hellborg, Jan Adolfsson, Jonas Bergh. (2011) Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden. Breast Cancer Research and Treatment 130:2, 553-560
CrossRef72
Katherine F. Croom, Sohita Dhillon. (2011) Bevacizumab. Drugs 71:16, 2213-2229
CrossRef73
Sheeba Irshad, Paul Ellis, Andrew Tutt. (2011) Molecular heterogeneity of triple-negative breast cancer and its clinical implications. Current Opinion in Oncology 23:6, 566-577
CrossRef74
Sara A. Hurvitz. (2011) Evolving options for the treatment of metastatic breast cancer: Progression-free survival as an endpoint. Cancer Treatment Reviews 37:7, 495-504
CrossRef75
E.A. Rakha, S. Chan. (2011) Metastatic Triple-negative Breast Cancer. Clinical Oncology 23:9, 587-600
CrossRef76
Charles Swanton. 2011. Chemotherapy and metastatic breast cancer. , 67-92.
CrossRef77
Sarah Barton, Nicholas C. Turner. 2011. Targeting triple-negative sporadic and hereditary BRCA-related metastatic breast cancer. , 050-066.
CrossRef78
David Miles. 2011. Targeting angiogenesis in metastatic breast cancer. , 101-119.
CrossRef79
Alberto J. Montero, Mauricio Escobar, Gilberto Lopes, Stefan Glück, Charles Vogel. (2011) Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe?. Current Oncology Reports
CrossRef80
Coralie Deladriere, Rut Lucas, María J. Vicent. 2011. Future Trends, Challenges, and Opportunities with Polymer-Based Combination Therapy in Cancer. , 805-837.
CrossRef81
Lesley J. Fallowfield, Anne Fleissig. (2011) The value of progression-free survival to patients with advanced-stage cancer. Nature Reviews Clinical Oncology 9:1, 41-47
CrossRef82
Sekeres, Mikkael A., . (2011) The Avastin Story. New England Journal of Medicine 365:15, 1454-1455
Full Text83
David B. Jackson, Anil K. Sood. (2011) Personalized cancer medicine—advances and socio-economic challenges. Nature Reviews Clinical Oncology 8:12, 735-741
CrossRef84
David A. Reardon, Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon, Anuradha Bulusu, Stevie Threatt, Allan H. Friedman, James J. Vredenburgh, Henry S. Friedman. (2011) Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. Journal of Neuro-Oncology
CrossRef85
J. Cortes, V. Calvo, N. Ramirez-Merino, J. O'Shaughnessy, A. Brufsky, N. Robert, M. Vidal, E. Munoz, J. Perez, S. Dawood, C. Saura, S. Di Cosimo, A. Gonzalez-Martin, M. Bellet, O. E. Silva, D. Miles, A. Llombart, J. Baselga. (2011) Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Annals of Oncology
CrossRef86
Michaela J. Higgins, José Baselga. (2011) Targeted therapies for breast cancer. Journal of Clinical Investigation 121:10, 3797-3803
CrossRef87
Hasan Korkaya, Suling Liu, Max S. Wicha. (2011) Breast cancer stem cells, cytokine networks, and the tumor microenvironment. Journal of Clinical Investigation 121:10, 3804-3809
CrossRef88
J. Chirgwin, S.L. Chua. (2011) Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: A clinical review. The Breast 20:5, 394-406
CrossRef89
Aspasia Soultati, Giannis Mountzios, Chrysoula Avgerinou, George Papaxoinis, Dimitrios Pectasides, Meletios-Athanassios Dimopoulos, Christos Papadimitriou. (2011) Endothelial vascular toxicity from chemotherapeutic agents: Preclinical evidence and clinical implications. Cancer Treatment Reviews
CrossRef90
Kenjiro Aogi, Norikazu Masuda, Shinji Ohno, Takashi Oda, Hiroji Iwata, Masahiro Kashiwaba, Yasuhiro Fujiwara, Shunji Kamigaki, Yoshinori Ito, Takayuki Ueno, Shigemitsu Takashima. (2011) First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study. Breast Cancer Research and Treatment 129:3, 829-838
CrossRef91
Bohuslav Melichar, Mario Plebani. (2011) Laboratory medicine: an essential partner in the care of cancer patients. Clinical Chemistry and Laboratory Medicine 49:10, 1575-1578
CrossRef92
S. Mehta, N. P. Hughes, F. M. Buffa, S. P. Li, R. F. Adams, A. Adwani, N. J. Taylor, N. C. Levitt, A. R. Padhani, A. Makris, A. L. Harris. (2011) Assessing Early Therapeutic Response to Bevacizumab in Primary Breast Cancer Using Magnetic Resonance Imaging and Gene Expression Profiles. JNCI Monographs 2011:43, 71-74
CrossRef93
Sara Rodríguez-Enríquez, Silvia Cecilia Pacheco-Velázquez, Juan Carlos Gallardo-Pérez, Alvaro Marín-Hernández, José Luis Aguilar-Ponce, Erika Ruiz-García, Luz María RuizGodoy-Rivera, Abelardo Meneses-García, Rafael Moreno-Sánchez. (2011) Multi-biomarker pattern for tumor identification and prognosis. Journal of Cellular Biochemistry 112:10, 2703-2715
CrossRef94
Amna Sher, Shenhong Wu. (2011) Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy–A meta-analysis. Acta Oncologica 50:7, 997-1005
CrossRef95
Li Tian, You Han Bae. (2011) Cancer nanomedicines targeting tumor extracellular pH. Colloids and Surfaces B: Biointerfaces
CrossRef96
Scott T. Tagawa, Matthew I. Milowsky, Stephanie Jeske, Madhu Mazumdar, Sophia Kung, Max Sung, Deborah Lehrer, Daniel Matulich, Jodi Selzer, John J. Wright, David M. Nanus. (2011) A Phase I Trial of Sorafenib Plus Gemcitabine and Capecitabine for Patients With Advanced Renal Cell Carcinoma. American Journal of Clinical Oncology 34:5, 443-448
CrossRef97
Nadine Dohollou, Gérard Ganem, Jean-Paul Guastalla, Rémy Salmon. (2011) Cancer du sein méta-analyse en première ligne. Oncologie 13:10-11, 758-777
CrossRef98
Denise A. Yardley, Eric Raefsky, Raul Castillo, Anup Lahiry, Richard LoCicero, Dana Thompson, Mythili Shastry, Howard A. Burris, John D. Hainsworth. (2011) Phase II Study of Neoadjuvant Weekly nab-Paclitaxel and Carboplatin, With Bevacizumab and Trastuzumab, As Treatment For Women With Locally Advanced HER2+ Breast Cancer. Clinical Breast Cancer 11:5, 297-305
CrossRef99
Brian P. Walcott, Gregory L. Cvetanovich, Zachary R. Barnard, Brian V. Nahed, Kristopher T. Kahle, William T. Curry. (2011) Surgical treatment and outcomes of metastatic breast cancer to the spine. Journal of Clinical Neuroscience 18:10, 1336-1339
CrossRef100
Rochelle R. Arvizo, Subinoy Rana, Oscar R. Miranda, Resham Bhattacharya, Vincent M. Rotello, Priyabrata Mukherjee. (2011) Mechanism of anti-angiogenic property of gold nanoparticles: role of nanoparticle size and surface charge. Nanomedicine: Nanotechnology, Biology and Medicine 7:5, 580-587
CrossRef101
Zheng-tao Zhou, Fu-xiang Zhou, Qing Wei, Li-yong Zou, Bin-fang Qin, Xu-shen Peng. (2011) Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer. Cancer Chemotherapy and Pharmacology 68:4, 1027-1032
CrossRef102
Robert S. Kerbel. (2011) Reappraising antiangiogenic therapy for breast cancer. The Breast 20, S56-S60
CrossRef103
Jarle B. Arnes, Ingunn M. Stefansson, Oddbjørn Straume, Jan P. Baak, Per E. Lønning, William D. Foulkes, Lars A. Akslen. (2011) Vascular proliferation is a prognostic factor in breast cancer. Breast Cancer Research and Treatment
CrossRef104
Nilay Sethi, Yibin Kang. (2011) Unravelling the complexity of metastasis — molecular understanding and targeted therapies. Nature Reviews Cancer 11:10, 735-748
CrossRef105
J. T. O'Connell, H. Sugimoto, V. G. Cooke, B. A. MacDonald, A. I. Mehta, V. S. LeBleu, R. Dewar, R. M. Rocha, R. R. Brentani, M. B. Resnick, E. G. Neilson, M. Zeisberg, R. Kalluri. (2011) VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proceedings of the National Academy of Sciences 108:38, 16002-16007
CrossRef106
Devika Gajria, Kim Feigin, Lee K. Tan, Sujata Patil, Stephanie Geneus, Maria Theodoulou, Larry Norton, Clifford A. Hudis, Tiffany A. Traina. (2011) Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer. Cancer 117:18, 4125-4131
CrossRef107
Roger Henriksson, Thomas Asklund, Hans Skovgaard Poulsen. (2011) Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. Journal of Neuro-Oncology 104:3, 639-646
CrossRef108
F. Cardoso, L. Fallowfield, A. Costa, M. Castiglione, E. Senkus, . (2011) Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 22:Supplement 6, vi25-vi30
CrossRef109
Vinochani Pillay, Hui K. Gan, Andrew M. Scott. (2011) Antibodies in oncology. New Biotechnology 28:5, 518-529
CrossRef110
Lori E. Dodd, Edward L. Korn, Boris Freidlin, Robert Gray, Suman Bhattacharya. (2011) An Audit Strategy for Progression-Free Survival. Biometrics 67:3, 1092-1099
CrossRef111
Susana Banerjee, Stan Kaye. (2011) The role of targeted therapy in ovarian cancer. European Journal of Cancer 47, S116-S130
CrossRef112
C. K. Lee, M. Hudson, M. Stockler, A. S. Coates, S. Ackland, V. Gebski, S. Lord, M. Friedlander, F. Boyle, R. J. Simes. (2011) A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. Breast Cancer Research and Treatment 129:2, 467-476
CrossRef113
Stephen R.D. Johnston. (2011) The role of chemotherapy and targeted agents in patients with metastatic breast cancer. European Journal of Cancer 47, S38-S47
CrossRef114
Titti Martinsson-Niskanen, Rikke Riisbro, Leonard Larsson, Lena Winstedt, Yvonne Stenberg, Steve Pakola, Jean-Marie Stassen, Steven Glazer. (2011) Monoclonal Antibody TB-403: A First-in-Human, Phase I, Double-Blind, Dose Escalation Study Directed Against Placental Growth Factor in Healthy Male Subjects. Clinical Therapeutics 33:9, 1142-1149
CrossRef115
Qiang Zhang. (2011) Repeated Confidence Intervals Under Fractional Brownian Motion in Long-Term Clinical Trials. Communications in Statistics - Simulation and Computation 40:8, 1130-1145
CrossRef116
K. D. Miller, A. O'Neill, E. A. Perez, A. D. Seidman, G. W. Sledge. (2011) A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group. Annals of Oncology
CrossRef117
Ignacio Garrido-Laguna, Manuel Hidalgo, Razelle Kurzrock. (2011) The inverted pyramid of biomarker-driven trials. Nature Reviews Clinical Oncology 8:9, 562-566
CrossRef118
Domenico Ribatti. (2011) Vascular normalization: a real benefit?. Cancer Chemotherapy and Pharmacology 68:2, 275-278
CrossRef119
C. Villanueva, L. Chaigneau, A. Dufresne, A. Thierry Vuillemin, U. Stein, M. Demarchi, F. Bazan, T. N’Guyen, X. Pivot. (2011) Phase II trial of paclitaxel and uracil–tegafur in metastatic breast cancer. TEGATAX trial. The Breast 20:4, 329-333
CrossRef120
Domenico Ribatti. (2011) Novel angiogenesis inhibitors: Addressing the issue of redundancy in the angiogenic signaling pathway. Cancer Treatment Reviews 37:5, 344-352
CrossRef121
Reshu Saini, Jason M. Warram, Anna G. Sorace, Heidi Umphrey, Kurt R. Zinn, Kenneth Hoyt. (2011) Model System Using Controlled Receptor Expression for Evaluating Targeted Ultrasound Contrast Agents. Ultrasound in Medicine & Biology 37:8, 1306-1313
CrossRef122
J.- C. Soria, J. Y. Blay, J. P. Spano, X. Pivot, Y. Coscas, D. Khayat. (2011) Added value of molecular targeted agents in oncology. Annals of Oncology 22:8, 1703-1716
CrossRef123
Ying Liu, Rulla M. Tamimi, Laura C. Collins, Stuart J. Schnitt, Hannah L. Gilmore, James L. Connolly, Graham A. Colditz. (2011) The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses’ Health Study. Breast Cancer Research and Treatment 129:1, 175-184
CrossRef124
Wenting Wu, Qian Shi, Daniel J. Sargent. (2011) Statistical Considerations for the Next Generation of Clinical Trials. Seminars in Oncology 38:4, 598-604
CrossRef125
David Planchard. (2011) Bevacizumab in non-small-cell lung cancer: a review. Expert Review of Anticancer Therapy 11:8, 1163-1179
CrossRef126
Isabelle Ray-Coquard, Axel Le Cesne. (2011) A role for maintenance therapy in managing sarcoma. Cancer Treatment Reviews
CrossRef127
Stephen Dyar, Alvaro Moreno-Aspitia. (2011) Triple-negative breast cancer and new treatment developments. Clinical Investigation 1:8, 1107-1118
CrossRef128
N. C. Tebbutt, F. Murphy, D. Zannino, K. Wilson, M. M. Cummins, E. Abdi, A. H. Strickland, R. M. Lowenthal, G. Marx, C. Karapetis, J. Shannon, D. Goldstein, S. S. Nayagam, R. Blum, L. Chantrill, R. J. Simes, T. J. Price, . (2011) Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology 22:8, 1834-1838
CrossRef129
Priya Rastogi, Marc E. Buyse, Sandra M. Swain, Samuel A. Jacobs, André Robidoux, Marcia K. Liepman, Eduardo R. Pajon, Philip A. Dy, Juan G. Posada, Marianne K. Melnik, Fanny Piette, Charles E. Geyer, Elfetherios P. Mamounas, Norman Wolmark. (2011) Concurrent Bevacizumab with a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy for HER2− Locally Advanced Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group. Clinical Breast Cancer 11:4, 228-234
CrossRef130
Adam Brufsky, Karen Hoelzer, Thaddeus Beck, Robert Whorf, Mark Keaton, Padma Nadella, Elisa Krill-Jackson, Joan Kroener, Edward Middleman, Michael Frontiera, Devchand Paul, Timothy Panella, Jane Bromund, Luping Zhao, Mauro Orlando, Fritz Tai, Martin D. Marciniak, Coleman Obasaju, John Hainsworth. (2011) A Randomized Phase II Study of Paclitaxel and Bevacizumab With and Without Gemcitabine as First-Line Treatment for Metastatic Breast Cancer. Clinical Breast Cancer 11:4, 211-220
CrossRef131
Evanthia T. Roussos, John S. Condeelis, Antonia Patsialou. (2011) Chemotaxis in cancer. Nature Reviews Cancer 11:8, 573-587
CrossRef132
Hanmei Xu, Li Pan, Yinling Ren, Yongjing Yang, Xiaofeng Huang, Zhendong Liu. (2011) RGD-Modified Angiogenesis Inhibitor HM-3 Dose: Dual Function during Cancer Treatment. Bioconjugate Chemistry 22:7, 1386-1393
CrossRef133
Iwona Ługowska, Wojciech Woźniak, Teresa Klepacka, Elżbieta Michalak, Katarzyna Szamotulska. (2011) A prognostic evaluation of vascular endothelial growth factor in children and young adults with osteosarcoma. Pediatric Blood & Cancer 57:1, 63-68
CrossRef134
Sonia P. Li, Anwar R. Padhani, N. Jane Taylor, Mark J. Beresford, Mei-Lin W. Ah-See, J. James Stirling, James A. d’Arcy, David J. Collins, Andreas Makris. (2011) Vascular characterisation of triple negative breast carcinomas using dynamic MRI. European Radiology 21:7, 1364-1373
CrossRef135
Akm Hossain, Alice Chen, Percy Ivy, Daniel J. Lenihan, Jonathan Kaltman, Wendy Taddei-Peters, Scot C. Remick. (2011) The Importance of Clinical Grading of Heart Failure and Other Cardiac Toxicities During Chemotherapy: Updating the Common Terminology Criteria for Clinical Trial Reporting. Heart Failure Clinics 7:3, 373-384
CrossRef136
Shu Tian, Haitian Quan, Chengying Xie, Haiyi Guo, Fangfang Lü, Yongping Xu, Jin Li, Liguang Lou. (2011) YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Science 102:7, 1374-1380
CrossRef137
Yuan Wu, Weili Sun, Jifeng Feng. (2011) Antiangiogenic therapy for breast cancer: current status and future perspectives. The Chinese-German Journal of Clinical Oncology 10:7, 373-379
CrossRef138
B. Neyns, J. Sadones, C. Chaskis, M. Dujardin, H. Everaert, S. Lv, J. Duerinck, O. Tynninen, N. Nupponen, A. Michotte, J. Greve. (2011) Phase II study of sunitinib malate in patients with recurrent high-grade glioma. Journal of Neuro-Oncology 103:3, 491-501
CrossRef139
Wouter B. Nagengast, Marjolijn N. Lub-de Hooge, Esther M.E. van Straten, Schelto Kruijff, Adrienne H. Brouwers, Wilfred F.A. den Dunnen, Johan R. de Jong, Harry Hollema, Rudi A. Dierckx, Nanno H. Mulder, Elisabeth G.E. de Vries, Harald J. Hoekstra, Geke A.P. Hospers. (2011) VEGF-SPECT with 111In-bevacizumab in stage III/IV melanoma patients. European Journal of Cancer 47:10, 1595-1602
CrossRef140
Manuel Koch, Fadi Hussein, Andreas Woeste, Carsten Gründker, Karl Frontzek, Günter Emons, Thomas Hawighorst. (2011) CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo. Breast Cancer Research and Treatment 128:2, 337-346
CrossRef141
Susana Banerjee. (2011) The combination of VEGF inhibitors and anti-oestrogen therapies in breast cancer. Steroids 76:8, 807-811
CrossRef142
Binghe Xu, Zefei Jiang, Sung-Bae Kim, Shiying Yu, Jifeng Feng, Artur Malzyner, Auro Giglio, Hyun C. Chung, Li Jun Shen, Daniel Lee Kay Pen. (2011) Biweekly gemcitabine–paclitaxel, gemcitabine–carboplatin, or gemcitabine–cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer 18:3, 203-212
CrossRef143
Meredith L. Rees, Aarif Y. Khakoo. (2011) Molecular Mechanisms of Hypertension and Heart Failure Due to Antiangiogenic Cancer Therapies. Heart Failure Clinics 7:3, 299-311
CrossRef144
Jan Nyrop Jakobsen, Jens Benn Sørensen. (2011) Review on clinical trials of targeted treatments in malignant mesothelioma. Cancer Chemotherapy and Pharmacology 68:1, 1-15
CrossRef145
Krzysztof Adamowicz, Jacek Jassem, Artur Katz, Everardo D. Saad. (2011) Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials. Cancer Treatment Reviews
CrossRef146
Aris Polyzos, Kostas Kalbakis, Nikolaos Kentepozidis, Stylianos Giassas, Antonia Kalykaki, Nikolaos Vardakis, Vasiliki Bozionelou, Emmanouel Saloustros, Emmanouel Kontopodis, Vassilis Georgoulias, Dimitris Mavroudis. (2011) Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab. Cancer Chemotherapy and Pharmacology 68:1, 217-223
CrossRef147
Rhodé Bijlsma, Elsken Wall, Arjen Witkamp. (2011) De behandeling van borstkanker. Huisarts en wetenschap
CrossRef148
Iben Kümler, Dorte Lisbet Nielsen. (2011) Trials of bevacizumab in breast cancer – a safety review. Expert Opinion on Drug Safety1-12
CrossRef149
A M Jubb, A Cesario, M Ferguson, M T Congedo, K C Gatter, F Lococo, A Mulè, F Pezzella. (2011) Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases. British Journal of Cancer 104:12, 1877-1881
CrossRef150
Xing Lv, Yan-Qun Xiang, Su-Mei Cao, Chao-Nan Qian, Ning-Wei Li, Ling Guo, Hai-Qiang Mai, Qiu-Yan Chen, Pei-Yu Huang, DongHua Luo, Ka-Jia Cao, Ming-Huang Hong, Xiang Guo. (2011) Prospective validation of the prognostic value of elevated serum vascular endothelial growth factor in patients with nasopharyngeal carcinoma: More distant metastases and shorter overall survival after treatment. Head & Neck 33:6, 780-785
CrossRef151
K. Zaman, X. Durando, J.-F. Baurain, Y. Humblet, F. Mazzeo, M. Bostnavaron, N. Meheust, S. Monnoyer-Favrel, J.-P. Machiels, J. Bauer. (2011) A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer. Breast Cancer Research and Treatment 127:3, 689-696
CrossRef152
Harold J. Burstein. (2011) Introduction: Current and Future Approaches to Chemotherapy in Patients With Resistant Breast Cancer. Seminars in Oncology 38, S1-S2
CrossRef153
William Small, Mary F. Mulcahy, Alfred Rademaker, David J. Bentrem, Al B. Benson, Bing Bing Weitner, Mark S. Talamonti. (2011) Phase II Trial of Full-Dose Gemcitabine and Bevacizumab in Combination With Attenuated Three-Dimensional Conformal Radiotherapy in Patients With Localized Pancreatic Cancer. International Journal of Radiation Oncology*Biology*Physics 80:2, 476-482
CrossRef154
F. A. B. Schutz, Y. Je, G. R. Azzi, P. L. Nguyen, T. K. Choueiri. (2011) Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Annals of Oncology 22:6, 1404-1412
CrossRef155
Denise A. Yardley, Howard A. Burris, Bobby L. Clark, Dianna Shipley, Mark Rubin, John Barton, Edward Arrowsmith, John D. Hainsworth. (2011) Hormonal Therapy Plus Bevacizumab in Postmenopausal Patients Who Have Hormone Receptor–Positive Metastatic Breast Cancer: A Phase II Trial of the Sarah Cannon Oncology Research Consortium. Clinical Breast Cancer 11:3, 146-152
CrossRef156
Hong-Bin Xu, Qing Xu, Ling Li. (2011) A literature-based meta-analysis taxane-based doublet versus single-agent taxane chemotherapy in patients with advanced breast cancer. Journal of Cancer Research and Clinical Oncology 137:6, 1005-1013
CrossRef157
Xiao Feng Hang, Wen Sheng Xu, Jun Xue Wang, Lei Wang, Hai Guang Xin, Rui Qi Zhang, Wu Ni. (2011) Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology 67:6, 613-623
CrossRef158
Cyrus Chargari, Krassen M. Kirov, Marc A. Bollet, Nicolas Magné, Lionel Védrine, Serge Cremades, Philippe Beuzeboc, Alain Fourquet, Youlia M. Kirova. (2011) Cardiac toxicity in breast cancer patients: From a fractional point of view to a global assessment. Cancer Treatment Reviews 37:4, 321-330
CrossRef159
Wilson Gonsalves, Apar Kishor Ganti. (2011) Targeted anti-cancer therapy in the elderly. Critical Reviews in Oncology/Hematology 78:3, 227-242
CrossRef160
Kostas N. Syrigos, Eleni Karapanagiotou, Paraskevi Boura, Christian Manegold, Kevin Harrington. (2011) Bevacizumab-Induced Hypertension. BioDrugs 25:3, 159-169
CrossRef161
Arup Bhattacharya. (2011) Methylselenocysteine – a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs. Expert Opinion on Drug Delivery 8:6, 749-763
CrossRef162
Marie-Christine Etienne-Grimaldi, Patricia Formento, Armelle Degeorges, Jean-Yves Pierga, Rémi Delva, Xavier Pivot, Florence Dalenc, Marc Espié, Corinne Veyret, Jean-Louis Formento, Mireille Francoual, Magali Piutti, Patricia de Crémoux, Gérard Milano. (2011) Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. British Journal of Clinical Pharmacology 71:6, 921-928
CrossRef163
N. Harbeck, M. S. Ewer, M. De Laurentiis, T. M. Suter, S. M. Ewer. (2011) Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. Annals of Oncology 22:6, 1250-1258
CrossRef164
James D MELLOR, Michelle CASSUMBHOY, Michael JEFFORD. (2011) Clinical guidance on the perioperative use of targeted agents in solid tumor oncology. Asia-Pacific Journal of Clinical Oncology 7:2, 106-113
CrossRef165
Katrien De Bock, Massimiliano Mazzone, Peter Carmeliet. (2011) Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?. Nature Reviews Clinical Oncology 8:7, 393-404
CrossRef166
Wei Zhang, Ginger E. Dutschman, Xin Li, Yung-Chi Cheng. (2011) Quantitation of paclitaxel and its two major metabolites using a liquid chromatography–electrospray ionization tandem mass spectrometry. Journal of Chromatography B
CrossRef167
Curt Peterson. (2011) Drug therapy of cancer. European Journal of Clinical Pharmacology 67:5, 437-447
CrossRef168
Esther M. Bridges, Adrian L. Harris. (2011) The angiogenic process as a therapeutic target in cancer. Biochemical Pharmacology 81:10, 1183-1191
CrossRef169
David F McDermott, Keith T Flaherty. (2011) Combination therapy for renal cell carcinoma: review of the clinical evidence. Clinical Investigation 1:5, 689-697
CrossRef170
Fabio A.B. Schutz, Denis L.F. Jardim, Youjin Je, Toni K. Choueiri. (2011) Haematologic toxicities associated with the addition of bevacizumab in cancer patients. European Journal of Cancer 47:8, 1161-1174
CrossRef171
David Berz, Harold Wanebo. (2011) Targeting the growth factors and angiogenesis pathways: Small molecules in solid tumors. Journal of Surgical Oncology 103:6, 574-586
CrossRef172
Ana M. Gonzalez-Angulo, Gabriel N. Hortobagyi, Lee M. Ellis. (2011) Targeted therapies: Peaking beneath the surface of recent bevacizumab trials. Nature Reviews Clinical Oncology
CrossRef173
Miguel Martin, Henri Roche, Tamas Pinter, John Crown, M John Kennedy, Louise Provencher, Frank Priou, Wolfgang Eiermann, Encarna Adrover, Istvan Lang, Manuel Ramos, Jean Latreille, Agnieszka Jagiełło-Gruszfeld, Tadeusz Pienkowski, Emilio Alba, Raymond Snyder, Sachin Almel, Janusz Rolski, Montserrat Munoz, Rebecca Moroose, Sara Hurvitz, Ana Baños, Henry Adewoye, Yong-Jiang Hei, Mary-Ann Lindsay, Matthieu Rupin, David Cabaribere, Yasmin Lemmerick, John R Mackey. (2011) Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. The Lancet Oncology 12:4, 369-376
CrossRef174
Alberto Zambelli, Matteo Giovanni Della Porta, Ermanno Eleuteri, Luciana De Giuli, Oronzo Catalano, Carlo Tondini, Alberto Riccardi. (2011) Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. The Breast 20:2, 176-183
CrossRef175
Sònia Tugues, Sina Koch, Laura Gualandi, Xiujuan Li, Lena Claesson-Welsh. (2011) Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer. Molecular Aspects of Medicine 32:2, 88-111
CrossRef176
Ana Ferreira, Cláudia Vieira, Ana Rodrigues, Deolinda Pereira, Helena Rodrigues, Cristina Dávila, Sandra Bento. (2011) Bevacizumab in the treatment of metastatic breast cancer: three case reports. Current Opinion in Oncology 23, S11-S19
CrossRef177
Nicholas J. Robert, Mansoor N. Saleh, Devchand Paul, Daniele Generali, Laurent Gressot, Mehmet S. Copur, Adam M. Brufsky, Susan E. Minton, Jeffrey K. Giguere, John W. Smith, Paul D. Richards, Diana Gernhardt, Xin Huang, Katherine F. Liau, Kenneth A. Kern, John Davis. (2011) Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial. Clinical Breast Cancer 11:2, 82-92
CrossRef178
Neil S. Horowitz, Richard T. Penson, Dan G. Duda, Emmanuelle di Tomaso, Yves Boucher, Marek Ancukiewicz, Kenneth S. Cohen, Suzanne Berlin, Carolyn N. Krasner, Marsha A. Moses, Rakesh K. Jain. (2011) Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma. Clinical Ovarian Cancer
CrossRef179
Rita Nanda. (2011) “Targeting” Triple-Negative Breast Cancer: The Lessons Learned From BRCA1-Associated Breast Cancers. Seminars in Oncology 38:2, 254-262
CrossRef180
L. Bengrine-Lefevre, P. Afchain, B. Chibaudel, H. Gervais, C. Tournigand, A. De Gramont, C. Louvet. (2011) Perforation de la cloison nasale et bevacizumab. La Revue de Médecine Interne 32:4, e43-e45
CrossRef181
O. L. Chinot, T. Motte Rouge, N. Moore, A. Zeaiter, A. Das, H. Phillips, Z. Modrusan, T. Cloughesy. (2011) AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Advances in Therapy 28:4, 334-340
CrossRef182
Aman U Buzdar. (2011) Anti-angiogenic therapies in metastatic breast cancer—an unfulfilled dream. The Lancet Oncology 12:4, 316-318
CrossRef183
(2011) Cancer drugs: remedy required. Nature Medicine 17:4, 514-514
CrossRef184
Peer Joensson, Birgit Hotz, Heinz Johannes Buhr, Hubert G. Hotz. (2011) A novel antiangiogenic approach for adjuvant therapy of pancreatic carcinoma. Langenbeck's Archives of Surgery 396:4, 535-541
CrossRef185
Mackenzie J. Smith, Robert W. Berger, Kanwal Minhas, Roger A. Moorehead, Brenda L. Coomber. (2011) Heterogeneity of vascular and progenitor cell compartments in tumours from MMTV-PyVmT transgenic mice during mammary cancer progression. International Journal of Experimental Pathology 92:2, 106-116
CrossRef186
Margarida Damasceno. (2011) Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer. Current Opinion in Oncology 23, S3-S9
CrossRef187
Anna C Navis, Bob C Hamans, An Claes, Arend Heerschap, Judith WM Jeuken, Pieter Wesseling, William PJ Leenders. (2011) Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models. The Journal of Pathology 223:5, 626-634
CrossRef188
M. Di Salvatore, A. Orlandi, C. Bagalà, M. Quirino, A. Cassano, A. Astone, C. Barone. (2011) Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line. Cell Proliferation 44:2, 139-146
CrossRef189
Siamack Sabrkhany, Arjan W. Griffioen, Mirjam G.A. oude Egbrink. (2011) The role of blood platelets in tumor angiogenesis. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1815:2, 189-196
CrossRef190
Umang Swami, Imran Chaudhary, Mohammad H. Ghalib, Sanjay Goel. (2011) Eribulin—A review of preclinical and clinical studies. Critical Reviews in Oncology/Hematology
CrossRef191
Joseph P. Erinjeri, Abigail J. Fong, Nancy E. Kemeny, Karen T. Brown, George I. Getrajdman, Stephen B. Solomon. (2011) Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer 117:6, 1296-1301
CrossRef192
Timothy Poterucha, Brian Burnette, Aminah Jatoi. (2011) A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab. Medical Oncology
CrossRef193
Armin Gerger, Melissa LaBonte, Heinz-Josef Lenz. (2011) Molecular Predictors of Response to Antiangiogenesis Therapies. The Cancer Journal 17:2, 134-141
CrossRef194
Orit Freedman, Eitan Amir, Camilla Zimmermann, Mark Clemons. (2011) Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials. Supportive Care in Cancer 19:3, 315-322
CrossRef195
Anastasia Pazaiti, Ian S Fentiman. (2011) Basal phenotype breast cancer: implications for treatment and prognosis. Women's Health 7:2, 181-202
CrossRef196
I. E. Smith, J.- Y. Pierga, L. Biganzoli, H. Cortes-Funes, C. Thomssen, X. Pivot, A. Fabi, B. Xu, D. Stroyakovskiy, F. A. Franke, B. Kaufman, P. Mainwaring, T. Pienkowski, B. De Valk, A. Kwong, J. L. Gonzalez-Trujillo, I. Koza, K. Petrakova, D. Pereira, K. I. Pritchard, . (2011) First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients. Annals of Oncology 22:3, 595-602
CrossRef197
George Dranitsaris, Ilse Truter, Martie S. Lubbe, Eitan Amir, William Evans. (2011) Advances in Cancer Therapeutics and Patient Access to New Drugs. PharmacoEconomics 29:3, 213-224
CrossRef198
Craig A. Mayr, June Yijuan Hou, Gary L. Goldberg, Dennis Yi-Shin Kuo. (2011) Angiogenesis and its modulation in the pathophysiology and treatment of endometrial carcinoma. Oncology Reviews 5:1, 43-48
CrossRef199
Sarah JL Payne, Louise Jones. (2011) Influence of the tumor microenvironment on angiogenesis. Future Oncology 7:3, 395-408
CrossRef200
Yu-Quan Xiong, Hui-Chuan Sun, Xiao-Dong Zhu, Wei Zhang, Peng-Yuan Zhuang, Ju-Bo Zhang, Hua-Xiang Xu, Ling-Qun Kong, Wei-Zhong Wu, Lun-Xiu Qin, Zhao-You Tang. (2011) Bevacizumab enhances chemosensitivity of hepatocellular carcinoma to adriamycin related to inhibition of survivin expression. Journal of Cancer Research and Clinical Oncology 137:3, 505-512
CrossRef201
Michael S Gordon. (2011) Antiangiogenic therapies: is VEGF-A inhibition alone enough?. Expert Review of Anticancer Therapy 11:3, 485-496
CrossRef202
Ursula A Matulonis. (2011) Bevacizumab and its use in epithelial ovarian cancer. Future Oncology 7:3, 365-379
CrossRef203
J. -P. Spano, J. -C. Thery. (2011) Place des thérapies ciblées chez la patiente âgée atteinte de cancer du sein. Oncologie 13:2-3, 97-101
CrossRef204
M. Golshan, J. E. Garber, R. Gelman, Nadine Tung, B. L. Smith, S. Troyan, C. C. Greenberg, E. P. Winer, P. Ryan. (2011) Does Neoadjuvant Bevacizumab Increase Surgical Complications in Breast Surgery?. Annals of Surgical Oncology 18:3, 733-737
CrossRef205
Brian M Slomovitz, Michael J Worley, Maurie Markman, Robert L Coleman. (2011) Emerging therapeutics for primary peritoneal cancer. Expert Opinion on Emerging Drugs 16:1, 71-84
CrossRef206
I. Arratibel-Echarren, K. Albright, J. Dalmau, M.R. Rosenfeld. (2011) Utilización de bevacizumab en las complicaciones neurológicas durante el tratamiento inicial de los gliomas malignos. Neurología 26:2, 74-80
CrossRef207
John M. L. Ebos, Robert S. Kerbel. (2011) Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nature Reviews Clinical Oncology 8:4, 210-221
CrossRef208
Patrizia Vici, Alessandra Fabi, Giulio Metro, Domenico Sergi, Diana Giannarelli, Luigi Di Lauro, Gerold Bepler, Federica Tomao, Francesco Cognetti, Francesca Conti, Massimo Lopez. (2011) Phase I–II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines. Cancer Chemotherapy and Pharmacology 67:3, 687-693
CrossRef209
J. Lemieux, P. J. Goodwin, L. J. Bordeleau, S. Lauzier, V. Theberge. (2011) Quality-of-Life Measurement in Randomized Clinical Trials in Breast Cancer: An Updated Systematic Review (2001-2009). JNCI Journal of the National Cancer Institute 103:3, 178-231
CrossRef210
Robert O. Dillman. (2011) Cancer Immunotherapy. Cancer Biotherapy & Radiopharmaceuticals 26:1, 1-64
CrossRef211
Clarisse Eveno, Christine le Maignan, Philippe Soyer, Marine Camus, Emmanuel Barranger, Marc Pocard. (2011) Late anastomotic colonic dehiscence due to antiangiogenic treatment, a specific drug-class complication requiring specific treatment: An example of pazopanib complication. Clinics and Research in Hepatology and Gastroenterology 35:2, 135-139
CrossRef212
Venkateswaran Subramaniam, Olga Ace, Gerald J. Prud'homme, Serge Jothy. (2011) Tranilast treatment decreases cell growth, migration and inhibits colony formation of human breast cancer cells. Experimental and Molecular Pathology 90:1, 116-122
CrossRef213
M. Aapro, C. Bernard-Marty, E. G. C. Brain, G. Batist, F. Erdkamp, K. Krzemieniecki, R. Leonard, A. Lluch, S. Monfardini, M. Ryberg, P. Soubeyran, U. Wedding. (2011) Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Annals of Oncology 22:2, 257-267
CrossRef214
G. von Minckwitz, H. Eidtmann, S. Loibl, J.- U. Blohmer, S.- D. Costa, P. A. Fasching, R. Kreienberg, J. Hilfrich, B. Gerber, C. Hanusch, T. Fehm, D. Strumberg, C. Solbach, V. Nekljudova, M. Untch, . (2011) Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Annals of Oncology 22:2, 301-306
CrossRef215
Igor A. Astsaturov, Neal J. Meropol, R. Katherine Alpaugh, Barbara A. Burtness, Jonathan D. Cheng, Sue McLaughlin, André Rogatko, Zhiheng Xu, James C. Watson, Louis M. Weiner, Steven J. Cohen. (2011) Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma. American Journal of Clinical Oncology 34:1, 70-75
CrossRef216
Kristan D. Guenterberg, Valerie P. Grignol, Kiran V. Relekar, Kimberly A. Varker, Helen X. Chen, Kari L. Kendra, Thomas E. Olencki, William E. Carson. (2011) A Pilot Study of Bevacizumab and Interferon-α2b in Ocular Melanoma. American Journal of Clinical Oncology 34:1, 87-91
CrossRef217
Jae-Bok Lee, Ok Hee Woo, Kyong Hwa Park, Sang Uk Woo, Dae Sik Yang, Ae-Ree Kim, Eun Sook Lee, Yeul Hong Kim, Jun Suk Kim, Jae Hong Seo. (2011) Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials. Investigational New Drugs 29:1, 182-188
CrossRef218
N B Leighl, J Bennouna, J Yi, N Moore, J Hambleton, H Hurwitz. (2011) Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. British Journal of Cancer 104:3, 413-418
CrossRef219
Naifu Liu, Xingwu Wang, Xiugui Sheng. (2011) ‘Triple negative’ epithelial ovarian cancer and pathologic markers for prognosis. Current Opinion in Obstetrics and Gynecology 23:1, 19-23
CrossRef220
Eleri Davies, Stephen Hiscox. (2011) New therapeutic approaches in breast cancer. Maturitas 68:2, 121-128
CrossRef221
Michaela J. Higgins, José Baselga. (2011) Breast cancer in 2010: Novel targets and therapies for a personalized approach. Nature Reviews Clinical Oncology 8:2, 65-66
CrossRef222
J. J. Biagi, A. M. Oza, H. I. ChalChal, R. Grimshaw, S. L. Ellard, U. Lee, H. Hirte, J. Sederias, S. P. Ivy, E. A. Eisenhauer. (2011) A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Annals of Oncology 22:2, 335-340
CrossRef223
Sumanta Kumar Pal, Barrett H. Childs, Mark Pegram. (2011) Triple negative breast cancer: unmet medical needs. Breast Cancer Research and Treatment 125:3, 627-636
CrossRef224
M. S. Rosati, C. Raimondi, G. Baciarello, P. Grassi, S. Giovannoni, E. Petrelli, M. L. Basile, M. Girolami, M. Di Seri, L. Frati. (2011) Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial (phase I-II). Annals of Oncology 22:2, 315-320
CrossRef225
Anna Dorothea Wagner, Christoph Thomssen, Johannes Haerting, Susanne Unverzagt, Anna Dorothea Wagner. 2011. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. .
CrossRef226
A. Ocana, I. F. Tannock. (2011) When Are "Positive" Clinical Trials in Oncology Truly Positive?. JNCI Journal of the National Cancer Institute 103:1, 16-20
CrossRef227
Tarik Mahfoud, Rachid Tanz, Mohamed Mesmoudi, Mohamed Réda Khmamouche, Aziz Bazine, Rachid Aassab, Nabil Ismaili, Saber Boutayeb, Mohamed Ichou, Hassan Errihani. (2011) Bevacizumab 5 or 7.5 mg/kg in Metastatic Colorectal Cancer Can Be Infused Safely Over 10 Minutes. Journal of Gastrointestinal Cancer
CrossRef228
Minoru Miyashita, Takanori Ishida, Kazuyuki Ishida, Kentaro Tamaki, Masakazu Amari, Mika Watanabe, Noriaki Ohuchi, Hironobu Sasano. (2011) Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates. Virchows Archiv 458:1, 65-72
CrossRef229
Guenther G. Steger, Rupert Bartsch. (2011) Trends and Novel Approaches in Neoadjuvant Treatment of Breast Cancer. Breast Care 6:6, 427-433
CrossRef230
Di Domenico Marina, Ricciardi Carmela, Fusco Alfredo, Pierantoni Giovanna Maria. (2011) Anti-VEGF Therapy in Breast and Lung Mouse Models of Cancers. Journal of Biomedicine and Biotechnology 2011, 1-4
CrossRef231
Jodi M. Saunus, Majid Momeny, Peter T. Simpson, Sunil R. Lakhani, Leonard Da Silva. (2011) Molecular Aspects of Breast Cancer Metastasis to the Brain. Genetics Research International 2011, 1-9
CrossRef232
Pia Vihinen, Outi Paija, Atte Kivisaari, Leena Koulu, Heikki Aho. (2011) Cutaneous lupus erythematosus after treatment with paclitaxel and bevacizumab for metastatic breast cancer: a case report. Journal of Medical Case Reports 5:1, 243
CrossRef233
Amedeo Amedei, Marisa Benagiano, Chiara della Bella, Elena Niccolai, Mario M. D'Elios. (2011) Novel Immunotherapeutic Strategies of Gastric Cancer Treatment. Journal of Biomedicine and Biotechnology 2011, 1-17
CrossRef234
Dusan Kotasek, Niall Tebbutt, Jayesh Desai, Stephen Welch, Lillian L Siu, Sheryl McCoy, Yu-Nien Sun, Jessica Johnson, Adeboye H Adewoye, Timothy Price. (2011) Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. BMC Cancer 11:1, 313
CrossRef235
K. Jhaveri, M. Dickler. (2011) Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF. Breast Diseases: A Year Book Quarterly 22:2, 181-184
CrossRef236
Anthony Jarkowski, Ashley E Glode, Edward J Spangenthal, Michael K. K Wong. (2011) Heart Failure Caused by Molecularly Targeted Therapies for Cancer. Pharmacotherapy 31:1, 62-75
CrossRef237
Mario Giuliano, Antonio Giordano, Summer Jackson, Kenneth R Hess, Ugo De Giorgi, Michal Mego, Beverly C Handy, Naoto T Ueno, Ricardo H Alvarez, Michelino De Laurentiis, Sabino De Placido, Vicente Valero, Gabriel N Hortobagyi, James M Reuben, Massimo Cristofanilli. (2011) Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Research 13:3, R67
CrossRef238
Federica Cuppone, Emilio Bria, Vanja Vaccaro, Fabio Puglisi, Alessandra Fabi, Isabella Sperduti, Paolo Carlini, Michele Milella, Cecilia Nisticò, Michelangelo Russillo, Paola Papaldo, Gianluigi Ferretti, Matti Aapro, Diana Giannarelli, Francesco Cognetti. (2011) Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. Journal of Experimental & Clinical Cancer Research 30:1, 54
CrossRef239
Filippo Bellati, Chiara Napoletano, Maria Luisa Gasparri, Valeria Visconti, Ilaria Grazia Zizzari, Ilary Ruscito, Jlenia Caccetta, Aurelia Rughetti, Pierluigi Benedetti-Panici, Marianna Nuti. (2011) Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View. Clinical and Developmental Immunology 2011, 1-16
CrossRef240
Edith A. Perez, Jean-Philippe Spano. (2011) Current and emerging targeted therapies for metastatic breast cancer. Cancern/a-n/a
CrossRef241
Johnny Kao, Eric C. Ko, Samuel Eisenstein, Andrew G. Sikora, Shibo Fu, Shu-hsia Chen. (2011) Targeting immune suppressing myeloid-derived suppressor cells in oncology. Critical Reviews in Oncology/Hematology 77:1, 12-19
CrossRef242
Amy M. Porter, J. Aubrey Waddell, Dominic A. Solimando. (2011) Cancer Chemotherapy Update - Paclitaxel and Bevacizumab Regimen for Metastatic Breast Cancer. Hospital Pharmacy 46:1, 19-22
CrossRef243
Fotios Loupakis, Annamaria Ruzzo, Lisa Salvatore, Chiara Cremolini, Gianluca Masi, Paolo Frumento, Marta Schirripa, Vincenzo Catalano, Nadia Galluccio, Emanuele Canestrari, Bruno Vincenzi, Daniele Santini, Katia Bencardino, Vincenzo Ricci, Mariangela Manzoni, Marco Danova, Giuseppe Tonini, Mauro Magnani, Alfredo Falcone, Francesco Graziano. (2011) Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer 11:1, 247
CrossRef244
I. Arratibel-Echarren, K. Albright, J. Dalmau, M.R. Rosenfeld. (2011) Use of Bevacizumab for neurological complications during initial treatment of malignant gliomas. Neurología (English Edition) 26:2, 74-80
CrossRef245
Thomas Bachelot, Agathe Bajard, Isabelle Ray-Coquard, Jocelyne Provencal, David Coeffic, Cécile Agostini, Martial Boisseau, Régis Kaphan, Dominique Dramais, Corina Oprea, Rose-Marie Ferri-Dessens, Jean-Paul Guastalla, David Perol. (2011) Final Results of ERASME-4: A Randomized Trial of First-Line Docetaxel plus either Capecitabine or Epirubicin for Metastatic Breast Cancer. Oncology 80:3-4, 262-268
CrossRef246
Shaheenah Dawood, Asim Jamal Shaikh, Thomas A. Buchholz, Javier Cortes, Massimo Cristofanilli, Sudeep Gupta, Ana M. Gonzalez-Angulo. (2011) The use of bevacizumab among women with metastatic breast cancer: A survey on clinical practice and the ongoing controversy. Cancern/a-n/a
CrossRef247
Michael Allen, J Louise Jones. (2011) Jekyll and Hyde: the role of the microenvironment on the progression of cancer. The Journal of Pathology 223:2, 163-177
CrossRef248
C. Rochlitz, T. Ruhstaller, S. Lerch, C. Spirig, J. Huober, T. Suter, M. Buhlmann, M. Fehr, A. Schonenberger, R. von Moos, R. Winterhalder, D. Rauch, A. Muller, M. Mannhart-Harms, R. Herrmann, B. Cliffe, M. Mayer, K. Zaman, . (2011) Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Annals of Oncology 22:1, 80-85
CrossRef249
Davide Tassinari, Sergio Sartori, Maximilian Papi, Fabrizio Drudi, Cinzia Castellani, Federica Carloni, Paola Tombesi, Luigi Lazzari-Agli. (2011) Bevacizumab in the Treatment of Advanced, Non-Squamous Non-Small Cell Lung Cancer: An Evidence-Based Approach. Oncology 80:5-6, 350-358
CrossRef250
Ayca Gucalp, Tiffany A. Traina. (2011) Triple-Negative Breast Cancer: Adjuvant Therapeutic Options. Chemotherapy Research and Practice 2011, 1-13
CrossRef251
Ewe Seng Ch'ng, Hasnan Jaafar, Sharifah Emilia Tuan Sharif. (2011) Breast Tumor Angiogenesis and Tumor-Associated Macrophages: Histopathologist's Perspective. Pathology Research International 2011, 1-13
CrossRef252
Thomas Bachelot, Olivier Tredan. 2011. Cancers du sein métastatiques. , 129-136.
CrossRef253
Erika P. Hamilton, Kimberly L. Blackwell. (2011) Safety of Bevacizumab in Patients with Metastatic Breast Cancer. Oncology 80:5-6, 314-325
CrossRef254
Maria de Sousa. (2011) An outsider's perspective—ecotaxis revisited: an integrative review of cancer environment, iron and immune system cells. Integrative Biology 3:4, 343
CrossRef255
A. von Drygalski, T. B. Tran, K. Messer, M. Pu, S. Corringham, C. Nelson, E. D. Ball. (2011) Obesity Is an Independent Predictor of Poor Survival in Metastatic Breast Cancer: Retrospective Analysis of a Patient Cohort Whose Treatment Included High-Dose Chemotherapy and Autologous Stem Cell Support. International Journal of Breast Cancer 2011, 1-8
CrossRef256
Junichi Matsubara, Yasuhiro Shimada, Ken Kato, Yushi Nagai, Satoru Iwasa, Takako E. Nakajima, Tetsuya Hamaguchi, Yasuhide Yamada, Seiichi Takagi, Kazuma Kobayashi, Akira Yoshioka, Norisuke Nakayama, Akihito Tsuji. (2011) Phase II Study of Bolus 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel as First-Line Therapy for Advanced Gastric Cancer. Oncology 81:5-6, 291-297
CrossRef257
Fausto Petrelli, Sandro Barni. (2010) Bevacizumab in advanced breast cancer: an opportunity as second-line therapy?. Medical Oncology
CrossRef258
Martin Augsten, Christina Hägglöf, Cristina Peña, Arne Östman. (2010) A Digest on the Role of the Tumor Microenvironment in Gastrointestinal Cancers. Cancer Microenvironment 3:1, 167-176
CrossRef259
A. Chan, D. W. Miles, X. Pivot. (2010) Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer. Annals of Oncology 21:12, 2305-2315
CrossRef260
Adrienne B. Gropper, Erica L. Mayer. (2010) Anti-Angiogenic Strategies in Breast Cancer: An Update. Current Breast Cancer Reports 2:4, 174-181
CrossRef261
S. Ressler, B. Mlineritsch, R. Greil. (2010) Triple Negative Breast Cancer. memo - Magazine of European Medical Oncology 3:4, 185-189
CrossRef262
Anthony D. Elias. (2010) Triple-Negative Breast Cancer. American Journal of Clinical Oncology 33:6, 637-645
CrossRef263
U. Hüttemann, E. Langer, A. Schönherr, K. Zwiefel, M. Neumann, W. Janni, S. Mohrmann. (2010) BRCA-Aktivität beim triple-negativen Mammakarzinom. Der Gynäkologe 43:12, 1002-1007
CrossRef264
E. L. Mayer, S. Dhakil, T. Patel, S. Sundaram, C. Fabian, M. Kozloff, R. Qamar, F. Volterra, H. Parmar, M. Samant, H. J. Burstein. (2010) SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Annals of Oncology 21:12, 2370-2376
CrossRef265
Myoung Hee Kang, Shi Nae Kim, Noe Kyeong Kim, Young-Iee Park, Young-Woo Kim, Keun Won Ryu, Jun Ho Lee, Jong Seok Lee, Sook Ryun Park. (2010) Clinical Outcomes and Prognostic Factors of Metastatic Gastric Carcinoma Patients Who Experience Gastrointestinal Perforation During Palliative Chemotherapy. Annals of Surgical Oncology 17:12, 3163-3172
CrossRef266
Ilse Roodink, William P.J. Leenders. (2010) Targeted therapies of cancer: Angiogenesis inhibition seems not enough. Cancer Letters 299:1, 1-10
CrossRef267
Shadia Jalal, Pablo Bedano, Lawrence Einhorn, Sumeet Bhatia, Rafat Ansari, Naftali Bechar, Karuna Koneru, Ramaswamy Govindan, Jingwei Wu, Menggang Yu, Bryan Schneider, Nasser Hanna. (2010) Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer. Journal of Thoracic Oncology 5:12, 2008-2011
CrossRef268
Mu-Tai Liu, Wen-Tao Huang, Ai-Yih Wang, Chia-Chun Huang, Chao-Yuan Huang, Tung-Hao Chang, Chu-Pin Pi, Hao-Han Yang. (2010) Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index. Supportive Care in Cancer 18:12, 1553-1564
CrossRef269
Gopa Iyer, Matthew I Milowsky, Dean F Bajorin. (2010) Novel strategies for treating relapsed/refractory urothelial carcinoma. Expert Review of Anticancer Therapy 10:12, 1917-1932
CrossRef270
D. Herr, I. Bekes, R. Kreienberg. (2010) Antikörper und Tyrosinkinaseinhibitoren. Der Gynäkologe 43:12, 996-1001
CrossRef271
Fusanori Yotsumoto, Eiji Oki, Eriko Tokunaga, Yoshihiko Maehara, Masahide Kuroki, Shingo Miyamoto. (2010) HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer. International Journal of Cancer 127:11, 2707-2717
CrossRef272
Tito Fojo, Julia Wilkerson. (2010) Bevacizumab and breast cancer: the E2100 outlier. The Lancet Oncology 11:12, 1117-1119
CrossRef273
Nicola Maurea, Carmela Coppola, Gianluca Ragone, Giuseppe Frasci, Annamaria Bonelli, Carmela Romano, Rosario Vincenzo Iaffaioli. (2010) Women survive breast cancer but fall victim to heart failure: the shadows and lights of targeted therapy. Journal of Cardiovascular Medicine 11:12, 861-868
CrossRef274
R. Bartsch, R. Ziebermayr. (2010) Metastatic breast cancer – ASCO 2010. memo - Magazine of European Medical Oncology 3:4, 159-162
CrossRef275
Lisa Carey, Eric Winer, Giuseppe Viale, David Cameron, Luca Gianni. (2010) Triple-negative breast cancer: disease entity or title of convenience?. Nature Reviews Clinical Oncology 7:12, 683-692
CrossRef276
L. Tookman, R. Roylance. (2010) New drugs for breast cancer. British Medical Bulletin 96:1, 111-129
CrossRef277
Adrian M Jubb, Adrian L Harris. (2010) Biomarkers to predict the clinical efficacy of bevacizumab in cancer. The Lancet Oncology 11:12, 1172-1183
CrossRef278
Kathy S. Albain, Lisa Carey, William J. Gradishar, Julie R. Gralow, Allan Lipton, Hope Rugo, Debu Tripathy, Susan Peck, Tristin Abair, Mark Pegram. (2010) Proceedings of the First Global Workshop on Breast Cancer: Pathways to the Evaluation and Clinical Development of Novel Agents for Breast Cancer. Clinical Breast Cancer 10:6, 421-439
CrossRef279
Hitomi Nagayama, Kazufumi Matsumoto, Naoyuki Isoo, Hideki Ohno, Naoyuki Takahashi, Takashi Nakaoka, Masaru Shinozaki, Makoto Watanabe, Yusuke Inoue, Fumitaka Nagamura, Naoki Oyaizu, Naohide Yamashita. (2010) Gastrointestinal bleeding during anti-angiogenic peptide vaccination in combination with gemcitabine for advanced pancreatic cancer. Clinical Journal of Gastroenterology 3:6, 307-317
CrossRef280
Nicolas Magné, Cyrus Chargari, Dhara MacDermed, Rosa Conforti, Lionel Védrine, Jean-Philippe Spano, David Khayat. (2010) Tomorrow's targeted therapies in breast cancer patients: What is the risk for increased radiation-induced cardiac toxicity?. Critical Reviews in Oncology/Hematology 76:3, 186-195
CrossRef281
Shaheenah Dawood. (2010) Triple-Negative Breast Cancer. Drugs 70:17, 2247-2258
CrossRef282
Foulkes, William D., Smith, Ian E., Reis-Filho, Jorge S., . (2010) Triple-Negative Breast Cancer. New England Journal of Medicine 363:20, 1938-1948
Full Text283
Claudia Andreetta, Alessandro M. Minisini, Manuela Miscoria, Fabio Puglisi. (2010) First-line chemotherapy with or without biologic agents for metastatic breast cancer. Critical Reviews in Oncology/Hematology 76:2, 99-111
CrossRef284
Patrick G. Morris. (2010) Advances in therapy: eribulin improves survival for metastatic breast cancer. Anti-Cancer Drugs 21:10, 885-889
CrossRef285
Stacy Moulder. (2010) Intrinsic resistance to chemotherapy in breast cancer. Women's Health 6:6, 821-830
CrossRef286
Ahmad M. Mansour, Leon A. Bynoe, John C. Welch, Richard Pesavento, Padmamalini Mahendradas, Focke Ziemssen, Sivakami A. Pai. (2010) Retinal vascular events after intravitreal bevacizumab. Acta Ophthalmologica 88:7, 730-735
CrossRef287
Yvonne Kienast, Frank Winkler. (2010) Therapy and prophylaxis of brain metastases. Expert Review of Anticancer Therapy 10:11, 1763-1777
CrossRef288
Hsin-Yu Yao, Chi-Ting Horng, Jiann-Torng Chen, Ming-Ling Tsai. (2010) Regression of choroidal metastasis secondary to breast carcinoma with adjuvant intravitreal injection of bevacizumab. Acta Ophthalmologica 88:7, e282-e283
CrossRef289
Isabel Álvarez López, Juan Haba Rodríguez, Amparo Ruiz Simón, Meritxell Bellet Ezquerra, Lourdes Calvo Martínez, Laura García Estévez, Álvaro Rodríguez Lescure, Dolores Isla Casado. (2010) SEOM clinical guidelines for the treatment of metastatic breast cancer. Clinical and Translational Oncology 12:11, 719-723
CrossRef290
Margaret EM Van Meter, Edward S Kim. (2010) Bevacizumab: current updates in treatment. Current Opinion in Oncology 22:6, 586-591
CrossRef291
Fabrice Andre, Narjiss Berrada, Christine Desmedt. (2010) Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients. Current Opinion in Oncology 22:6, 547-551
CrossRef292
Cécile Ortholan, Jérôme Durivault, Jean-Michel Hannoun-Levi, Mélanie Guyot, Christine Bourcier, Damien Ambrosetti, Stephen Safe, Gilles Pagès. (2010) Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: A new paradigm for understanding the therapeutic effect of combined treatment. European Journal of Cancer 46:16, 3022-3036
CrossRef293
M. De Laurentiis, D. Cianniello, R. Caputo, B Stanzione, G. Arpino, S. Cinieri, V. Lorusso, S. De Placido. (2010) Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treatment Reviews 36, S80-S86
CrossRef294
Dianne C. Mitchell, Brad A. Bryan. (2010) Anti-angiogenic therapy: Adapting strategies to overcome resistant tumors. Journal of Cellular Biochemistry 111:3, 543-553
CrossRef295
Sang Joon Shin, Hei-Cheul Jeung, Joong Bae Ahn, Sun Young Rha, Jae Kyung Roh, Kyung Soo Park, Dal-Hyun Kim, Chin Kim, Hyun Cheol Chung. (2010) A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. Investigational New Drugs 28:5, 650-658
CrossRef296
Hirotsugu Kenmotsu, Masahiro Yasunaga, Koichi Goto, Tatsuya Nagano, Jun-ichiro Kuroda, Yoshikatsu Koga, Amane Takahashi, Yutaka Nishiwaki, Yasuhiro Matsumura. (2010) The antitumor activity of NK012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts. Cancer 116:19, 4597-4604
CrossRef297
Miguel Quintela-Fandino, Antonio González-Martín, Ramon Colomer. (2010) Targeting cytoskeleton reorganisation as antimetastatic treatment. Clinical and Translational Oncology 12:10, 662-669
CrossRef298
Ryan M Tarantola, James C Folk, H Culver Boldt, Vinit B Mahajan. (2010) INTRAVITREAL BEVACIZUMAB DURING PREGNANCY. Retina 30:9, 1405-1411
CrossRef299
Carlo Palmieri, Jonathan Krell, Colin R. James, Catherine Harper-Wynne, Vivek Misra, Susan Cleator, David Miles. (2010) Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nature Reviews Clinical Oncology 7:10, 561-574
CrossRef300
Catherine Oakman, Giuseppe Viale, Angelo Di Leo. (2010) Management of triple negative breast cancer. The Breast 19:5, 312-321
CrossRef301
Archontoula Stoffel. (2010) Targeted Therapies for Solid Tumors. BioDrugs 24:5, 303-316
CrossRef302
Monica Giovannini, Daniela Aldrighetti, Patrizia Zucchinelli, Carmen Belli, Eugenio Villa. (2010) Antiangiogenic strategies in breast cancer management. Critical Reviews in Oncology/Hematology 76:1, 13-35
CrossRef303
Christopher K. Fuller, John A. Charlson, Steven K. Dankle, Thomas J. Russell. (2010) Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy. Journal of the American Academy of Dermatology 63:4, e83-e84
CrossRef304
David Ternant, Nicolas Cézé, Thierry Lecomte, Danielle Degenne, Anne-Claire Duveau, Hervé Watier, Etienne Dorval, Gilles Paintaud. (2010) An Enzyme-Linked Immunosorbent Assay to Study Bevacizumab Pharmacokinetics. Therapeutic Drug Monitoring 32:5, 647-652
CrossRef305
B. F. El-Rayes, M. Zalupski, T. Bekai-Saab, L. K. Heilbrun, N. Hammad, B. Patel, S. Urba, A. F. Shields, U. Vaishampayan, S. Dawson, K. Almhanna, D. Smith, P. A. Philip. (2010) A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Annals of Oncology 21:10, 1999-2004
CrossRef306
Przemyslaw Twardowski, Walter M. Stadler, Paul Frankel, Primo N. Lara, Christopher Ruel, Gurkamal Chatta, Elisabeth Heath, David I. Quinn, David R. Gandara. (2010) Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial. Urology 76:4, 923-926
CrossRef307
I. Brana, J. Tabernero. (2010) Cardiotoxicity. Annals of Oncology 21:Supplement 7, vii173-vii179
CrossRef308
Monica Fornier. (2010) Ixabepilone Plus Capecitabine for Breast Cancer Patients With an Early Metastatic Relapse After Adjuvant Chemotherapy: Two Clinical Trials. Clinical Breast Cancer 10:5, 352-358
CrossRef309
N. Berrada, S. Delaloge, F. Andre. (2010) Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?. Annals of Oncology 21:Supplement 7, vii30-vii35
CrossRef310
Katalin Boér, István Láng, Antonio Llombart-Cussac, Inger Andreasson, Guillermo L. Vivanco, Nick Sanders, Gillian M. Pover, Elizabeth Murray. (2010) Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study. Investigational New Drugs
CrossRef311
A Mailliez, C Baldini, J T Van, V Servent, Y Mallet, J Bonneterre. (2010) Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients. British Journal of Cancer 103:6, 772-775
CrossRef312
N. Saijo. (2010) Progress in Cancer Chemotherapy with Special Stress on Molecular-targeted Therapy. Japanese Journal of Clinical Oncology 40:9, 855-862
CrossRef313
H. Wildiers, C. Fontaine, P. Vuylsteke, M. Martens, J. L. Canon, W. Wynendaele, C. Focan, J. Greve, P. Squifflet, R. Paridaens. (2010) Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment 123:2, 463-469
CrossRef314
Giuseppe Curigliano, Erica L. Mayer, Harold J. Burstein, Eric P. Winer, Aron Goldhirsch. (2010) Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review. Progress in Cardiovascular Diseases 53:2, 94-104
CrossRef315
Stacy L. Moulder. (2010) Novel Cytotoxic Backbones and Targeted Therapies: Recent Data and Ongoing Clinical Trials. Clinical Breast Cancer 10:0, S30-S40
CrossRef316
Christopher Lobo, Gilberto Lopes, Odalys Baez, Aurelio Castrellon, Annapoorna Ferrell, Connie Higgins, Erin Hurley, Judith Hurley, Isildinha Reis, Stephen Richman, Pearl Seo, Orlando Silva, Joyce Slingerland, Keleni Tukia, Catherine Welsh, Stefan Glück. (2010) Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment 123:2, 427-435
CrossRef317
Marc C. Chamberlain. (2010) Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer 116:17, 3988-3999
CrossRef318
Elizabeth A. Comen, Monica N. Fornier. (2010) Algorithms for the Treatment of Patients With Metastatic Breast Cancer and Prior Exposure to Taxanes and Anthracyclines. Clinical Breast Cancer 10:0, S7-S19
CrossRef319
Malorye Allison. (2010) Avastin's commercial march suffers setback. Nature Biotechnology 28:9, 879-880
CrossRef320
Sally Greenberg, Hope S. Rugo. (2010) Challenging Clinical Scenarios: Treatment of Patients With Triple-Negative or Basal-Like Metastatic Breast Cancer. Clinical Breast Cancer 10:0, S20-S29
CrossRef321
Otto Metzger Filho, Kamal S. Saini, Hatem A. Azim, Ahmad Awada. (2010) Prevention and management of major side effects of targeted agents in breast cancer. Critical Reviews in Oncology/Hematology
CrossRef322
Rodrigo O. B. Maegawa, Shou-Ching Tang. (2010) Triple-Negative Breast Cancer: Unique Biology and Its Management. Cancer Investigation 28:8, 878-883
CrossRef323
Andrés García Palomo. (2010) Therapeutic approaches in young women with advanced or metastatic breast cancer. Breast Cancer Research and Treatment 123:S1, 49-52
CrossRef324
M. Vassilakopoulou, G. Mountzios, C. Papamechael, A.D. Protogerou, K. Aznaouridis, P. Katsichti, K. Venetsanou, M.-A. Dimopoulos, I. Ikonomidis, C.A. Papadimitriou. (2010) Paclitaxel chemotherapy and vascular toxicity as assessed by flow-mediated and nitrate-mediated vasodilatation. Vascular Pharmacology 53:3-4, 115-121
CrossRef325
Quinn S. Wells, Daniel J. Lenihan. (2010) Reversibility of Left Ventricular Dysfunction Resulting from Chemotherapy: Can This Be Expected?. Progress in Cardiovascular Diseases 53:2, 140-148
CrossRef326
F.- C. Bidard, C. Mathiot, A. Degeorges, M.- C. Etienne-Grimaldi, R. Delva, X. Pivot, C. Veyret, L. Bergougnoux, P. de Cremoux, G. Milano, J.- Y. Pierga. (2010) Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Annals of Oncology 21:9, 1765-1771
CrossRef327
Richard M. Zuniga, Roy Torcuator, Rajan Jain, John Anderson, Thomas Doyle, Lonni Schultz, Tom Mikkelsen. (2010) Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. Journal of Neuro-Oncology 99:2, 237-242
CrossRef328
Halina Frydman, Michael Szarek. (2010) Estimation of overall survival in an ‘illness-death’ model with application to the vertical transmission of HIV-1. Statistics in Medicine 29:19, 2045-2054
CrossRef329
Sofia Barluenga, Rajamalleswaramma Jogireddy, Girish K. Koripelly, Nicolas Winssinger. (2010) In Vivo Efficacy of Natural Product-Inspired Irreversible Kinase Inhibitors. ChemBioChem 11:12, 1692-1699
CrossRef330
T. Fojo, C. Grady. (2010) Response: Re: How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question. JNCI Journal of the National Cancer Institute 102:15, 1207-1210
CrossRef331
Pia P. Vihinen, Micaela Hernberg, Meri-Sisko Vuoristo, Kristiina Tyynelä, Marjut Laukka, Johan Lundin, Johanna Ivaska, Seppo Pyrhönen. (2010) A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-α2a as first line treatment in metastatic melanoma. Melanoma Research 20:4, 318-325
CrossRef332
H. Mukai. (2010) Targeted Therapy in Breast Cancer: Current Status and Future Directions. Japanese Journal of Clinical Oncology 40:8, 711-716
CrossRef333
Patricia R. Blank, Konstantin J. Dedes, Thomas D. Szucs. (2010) Cost Effectiveness of Cytotoxic and Targeted Therapy for Metastatic Breast Cancer. PharmacoEconomics 28:8, 629-647
CrossRef334
F. Barlesi, C. Balleyguier, B. Besse, F. Bonodeau, F. Brenac, O. Corneloup, E. Dansin, G. Ferretti, J. Y. Gaubert, R. Gervais, C. Lacombe, A. Loundou, D. Moro-Sibilot, D. Planchard, A. Scherpereel, Y. Menu. (2010) Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors. Annals of Oncology 21:8, 1682-1686
CrossRef335
K. Tsujino, J. Shiraishi, T. Tsuji, T. Kurata, T. Kawaguchi, A. Kubo, M. Takada. (2010) Is response rate increment obtained by molecular targeted agents related to survival benefit in the phase III trials of advanced cancer?. Annals of Oncology 21:8, 1668-1674
CrossRef336
Anastasia Constantinidou, Robin L Jones, Jorge S Reis-Filho. (2010) Beyond triple-negative breast cancer: the need to define new subtypes. Expert Review of Anticancer Therapy 10:8, 1197-1213
CrossRef337
Manuela Schmidinger, Joaquim Bellmunt. (2010) Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treatment Reviews 36:5, 416-424
CrossRef338
Susana M. Campos, Suzanne T. Berlin, Leroy M. Parker, Wendy Y. Chen, Craig A. Bunnell, Tina Atkinson, Julie Lee, Ursula Matulonis, Michelle S. Hirsch, Lyndsay Harris, Carolyn N. Krasner. (2010) Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. International Journal of Clinical Oncology 15:4, 390-398
CrossRef339
E. Gabriela Chiorean, Srikar Malireddy, Anne E. Younger, David R. Jones, Mary-Jane Waddell, Melissa I. Sloop, Menggang Yu, Stephen D. Hall, Bryan Schneider, Christopher J. Sweeney. (2010) A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 66:3, 441-448
CrossRef340
Mao Mao An, Zui Zou, Hui Shen, Ping Liu, Meng Li Chen, Yong Bing Cao, Yuan Ying Jiang. (2010) Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. European Journal of Clinical Pharmacology 66:8, 813-821
CrossRef341
Sara A. Hurvitz, Heather J. Allen, Rebecca L. Moroose, David Chan, Christopher Hagenstad, Steven H. Applebaum, Giribala Patel, Eddie H. Hu, Nancy Ryba, Lii-Shin Lin, HeJing Wang, John Glaspy, Dennis J. Slamon, Fairooz Kabbinavar. (2010) A Phase II Trial of Docetaxel With Bevacizumab as First-line Therapy for HER2-Negative Metastatic Breast Cancer (TORI B01). Clinical Breast Cancer 10:4, 307-312
CrossRef342
Min S Park, Vinod Ravi, Dejka M Araujo. (2010) Inhibiting the VEGF–VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Current Opinion in Oncology 22:4, 351-355
CrossRef343
Stefan Stortecky, Thomas M Suter. (2010) Insights into cardiovascular side-effects of modern anticancer therapeutics. Current Opinion in Oncology 22:4, 312-317
CrossRef344
I. Floriani, S. Garattini, V. Torri. (2010) Looking for efficiency rather than efficacy in randomized controlled trials in oncology. Annals of Oncology 21:7, 1391-1393
CrossRef345
George W. Sledge, Aparna C. Jotwani, Lida Mina. (2010) Targeted Therapies in Early-Stage Breast Cancer: Achievements and Promises. Surgical Oncology Clinics of North America 19:3, 669-679
CrossRef346
A. Valachis, N. P. Polyzos, N. Α. Patsopoulos, V. Georgoulias, D. Mavroudis, D. Mauri. (2010) Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Research and Treatment 122:1, 1-7
CrossRef347
Valentina Guarneri, David Miles, Nicholas Robert, Véronique Diéras, John Glaspy, Ian Smith, Christoph Thomssen, Laura Biganzoli, Tanya Taran, PierFranco Conte. (2010) Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Research and Treatment 122:1, 181-188
CrossRef348
Valentina Macrinici, Edward Romond. (2010) Clinical Updates on EGFR/HER Targeted Agents in Early-Stage Breast Cancer. Clinical Breast Cancer 10:0, E38-E46
CrossRef349
Gabriel N. Hortobagyi, Henry L. Gomez, Rubi K. Li, Hyun-Cheol Chung, Luis E. Fein, Valorie F. Chan, Jacek Jassem, Guillermo L. Lerzo, Xavier B. Pivot, Fernando Hurtado de Mendoza, Binghe Xu, Linda T. Vahdat, Ronald A. Peck, Pralay Mukhopadhyay, Henri H. Roché. (2010) Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Research and Treatment 122:2, 409-418
CrossRef350
Nicholas J. Robert. (2010) Overall survival in metastatic breast cancer: always our quest but not necessarily a primary endpoint. Breast Cancer Research and Treatment 122:1, 9-10
CrossRef351
C. G. Murphy, M. Khasraw, A. D. Seidman. (2010) Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer. Breast Cancer Research and Treatment 122:1, 177-179
CrossRef352
M. Kozloff, E. Chuang, A. Starr, P. A. Gowland, P. E. Cataruozolo, M. Collier, L. Verkh, X. Huang, K. A. Kern, K. Miller. (2010) An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Annals of Oncology 21:7, 1436-1441
CrossRef353
T. Hawighorst, W. Stein, C. Gründker, G. Emons. (2010) Angiogenese in Reproduktionsmedizin und gynäkologischer Onkologie. Der Gynäkologe 43:7, 595-600
CrossRef354
Christina Derleth, Ingrid A. Mayer. (2010) Antiangiogenic Therapies in Early-Stage Breast Cancer. Clinical Breast Cancer 10:0, E23-E31
CrossRef355
Maria Alsina, Manuel Ruiz-Echarri, Jaume Capdevila, Eva Muñoz, Josep Tabernero. (2010) Biomarkers for Therapies Directed at Angiogenesis. Current Colorectal Cancer Reports 6:3, 133-143
CrossRef356
Melinda L. Telli, James M. Ford. (2010) Novel Treatment Approaches for Triple-Negative Breast Cancer. Clinical Breast Cancer 10:0, E16-E22
CrossRef357
Roshani R. Patel, Surojeet Sengupta, Helen R. Kim, Andres J. Klein-Szanto, Jennifer R. Pyle, Fang Zhu, Tianyu Li, Eric A. Ross, Salewa Oseni, Joseph Fargnoli, V. Craig Jordan. (2010) Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: A potential clinical application of angiogenesis inhibitors. European Journal of Cancer 46:9, 1537-1553
CrossRef358
Bristi Basu, Tim Eisen. (2010) Perspectives in drug development for metastatic renal cell cancer. Targeted Oncology 5:2, 139-156
CrossRef359
Leslie M. Randall, Bradley J. Monk. (2010) Bevacizumab toxicities and their management in ovarian cancer. Gynecologic Oncology 117:3, 497-504
CrossRef360
Edith A. Perez, Tejal Patel, Alvaro Moreno-Aspitia. (2010) Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Research and Treatment 121:2, 261-271
CrossRef361
Guenther G. Steger, Jitka Abrahámová, Florin Bacanu, Stephen Brincat, Arija Brize, Alvydas Česas, Tanja Čufer, Magdolna Dank, Renata Duchnowska, Alexandru Eniu, Jacek Jassem, Zsuzsanna Kahán, Erika Matos, Peeter Padrik, Signe Plāte, Helis Pokker, Gunta Purkalne, Constanta Timcheva, Valentina Tzekova, Rostislav Vyzula, Christoph C. Zielinski. (2010) Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel. Wiener klinische Wochenschrift 122:11-12, 368-379
CrossRef362
Patrice Viens, Carole Tarpin, Henri Roche, François Bertucci. (2010) Systemic therapy of inflammatory breast cancer from high-dose chemotherapy to targeted therapies. Cancer 116:S11, 2829-2836
CrossRef363
Christina I. Herold, Benjamin Djulbegovic, Iztok Hozo, Gary H. Lyman. (2010) Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer. Breast Cancer Research and Treatment 121:3, 771-776
CrossRef364
Marc Buyse, Daniel J. Sargent, Axel Grothey, Alastair Matheson, Aimery de Gramont. (2010) Biomarkers and surrogate end points—the challenge of statistical validation. Nature Reviews Clinical Oncology 7:6, 309-317
CrossRef365
Patrick G Morris, Heather L McArthur, Clifford Hudis, Larry Norton. (2010) Dose-dense chemotherapy for breast cancer: what does the future hold?. Future Oncology 6:6, 951-965
CrossRef366
Jane Hurtig. (2010) Managing Patients With Advanced and Metastatic Breast Cancer. Clinical Journal of Oncology Nursing 14:3, 313-323
CrossRef367
Sarah Sinclair, Sandra M. Swain. (2010) Primary systemic chemotherapy for inflammatory breast cancer. Cancer 116:S11, 2821-2828
CrossRef368
Alejandro Forner, Carlos Rodríguez De Lope, María Reig, Jordi Bruix. (2010) Tratamiento del carcinoma hepatocelular avanzado. Gastroenterología y Hepatología 33:6, 461-468
CrossRef369
Lisa A. Carey. (2010) Through a Glass Darkly: Advances in Understanding Breast Cancer Biology, 2000-2010. Clinical Breast Cancer 10:3, 188-195
CrossRef370
Hiroyuki Konno, Masayoshi Yamamoto, Manabu Ohta. (2010) Recent concepts of antiangiogenic therapy. Surgery Today 40:6, 494-500
CrossRef371
Carlos H. Barrios, Mei-Ching Liu, Soo Chin Lee, Laurence Vanlemmens, Jean-Marc Ferrero, Toshio Tabei, Xavier Pivot, Hiroji Iwata, Kenjiro Aogi, Roberto Lugo-Quintana, Nadia Harbeck, Marla J. Brickman, Ke Zhang, Kenneth A. Kern, Miguel Martin. (2010) Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Research and Treatment 121:1, 121-131
CrossRef372
Geoffrey Y. Ku, David H. Ilson. (2010) Esophagogastric cancer: Targeted agents. Cancer Treatment Reviews 36:3, 235-248
CrossRef373
Volkmar Müller, Catherine Alix-Panabières, Klaus Pantel. (2010) Insights into minimal residual disease in cancer patients: Implications for anti-cancer therapies. European Journal of Cancer 46:7, 1189-1197
CrossRef374
Jonathan Sleeman, Patricia S. Steeg. (2010) Cancer metastasis as a therapeutic target. European Journal of Cancer 46:7, 1177-1180
CrossRef375
Alvaro Moreno-Aspitia. (2010) Clinical overview of sorafenib in breast cancer. Future Oncology 6:5, 655-663
CrossRef376
Carol Townsley, Amit Oza. (2010) Antiangiogenic therapies in ovarian cancer. Therapy 7:3, 277-284
CrossRef377
N. Steeghs, T. J. Rabelink, J. op 't Roodt, E. Batman, F. H. M. Cluitmans, N. I. Weijl, E. de Koning, H. Gelderblom. (2010) Reversibility of capillary density after discontinuation of bevacizumab treatment. Annals of Oncology 21:5, 1100-1105
CrossRef378
Vishal Ranpura, Bhargava Pulipati, David Chu, Xiaolei Zhu, Shenhong Wu. (2010) Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis. American Journal of Hypertension 23:5, 460-468
CrossRef379
F. Cardoso, E. Senkus-Konefka, L. Fallowfield, A. Costa, M. Castiglione, . (2010) Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21:Supplement 5, v15-v19
CrossRef380
Ana Bosch, Pilar Eroles, Rosa Zaragoza, Juan R. Viña, Ana Lluch. (2010) Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research. Cancer Treatment Reviews 36:3, 206-215
CrossRef381
Louis M. Weiner, Rishi Surana, Shangzi Wang. (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology 10:5, 317-327
CrossRef382
Faisal Azam, Shaveta Mehta, Adrian L. Harris. (2010) Mechanisms of resistance to antiangiogenesis therapy. European Journal of Cancer 46:8, 1323-1332
CrossRef383
Rebecca L Stone, Anil K Sood, Robert L Coleman. (2010) Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. The Lancet Oncology 11:5, 465-475
CrossRef384
Karni S. Moshal, Karine F. Ferri-Lagneau, TinChung Leung. (2010) Zebrafish Model: Worth Considering in Defining Tumor Angiogenesis. Trends in Cardiovascular Medicine 20:4, 114-119
CrossRef385
Lisa Rydén, Karin Jirström, Monica Haglund, Olle Stål, Mårten Fernö. (2010) Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Research and Treatment 120:2, 491-498
CrossRef386
B. Seruga, P. C. Hertz, L. W. Le, I. F. Tannock. (2010) Global drug development in cancer: a cross-sectional study of clinical trial registries. Annals of Oncology 21:4, 895-900
CrossRef387
Gerald W. Prager, Eva-Maria Lackner, Maria-Theresa Krauth, Matthias Unseld, Marina Poettler, Sylvia Laffer, Sabine Cerny-Reiterer, Wolfgang Lamm, Gabriela V. Kornek, Bernd R. Binder, Christoph C. Zielinski, Peter Valent. (2010) Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab. Molecular Oncology 4:2, 150-160
CrossRef388
Haritha Samaranayake, Ann-Marie Määttä, Jere Pikkarainen, Seppo Ylä-Herttuala. (2010) Future Prospects and Challenges of Antiangiogenic Cancer Gene Therapy. Human Gene Therapy 21:4, 381-396
CrossRef389
Kun Yang, You-Juan Wang, Xue-Rong Chen, Hai-Ning Chen. (2010) Effectiveness and Safety of Bevacizumab for Unresectable Non-Small-Cell Lung Cancer. Clinical Drug Investigation 30:4, 229-241
CrossRef390
Susan Onami, Melanie Ozaki, Joanne E. Mortimer, Sumanta Kumar Pal. (2010) Male breast cancer: An update in diagnosis, treatment and molecular profiling. Maturitas 65:4, 308-314
CrossRef391
Denise A. Yardley. (2010) Integrating Bevacizumab Into the Treatment of Patients With Early-Stage Breast Cancer: Focus on Cardiac Safety. Clinical Breast Cancer 10:2, 119-129
CrossRef392
Vishal Ranpura, Sanjaykumar Hapani, Jeff Chuang, Shenhong Wu. (2010) Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials. Acta Oncologica 49:3, 287-297
CrossRef393
A I Vitry. (2010) Reporting of Studies on New Medicines in Major Medical Journals: A Case Study in Breast Cancer. Clinical Pharmacology & Therapeutics 87:4, 398-400
CrossRef394
Debashish Bose, Funda Meric-Bernstam, Wayne Hofstetter, David A Reardon, Keith T Flaherty, Lee M Ellis. (2010) Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. The Lancet Oncology 11:4, 373-382
CrossRef395
Andreas Pircher, I. Heidegger, E. Gunsilius, W. Hilbe. (2010) Biomarkers of angiogenesis and their role in clinical oncology. memo - Magazine of European Medical Oncology 3:1, 27-32
CrossRef396
Adrian M. Jubb, Elizabeth J. Soilleux, Helen Turley, Graham Steers, Andrew Parker, Irene Low, Jennifer Blades, Ji-Liang Li, Paul Allen, Russell Leek, Irene Noguera-Troise, Kevin C. Gatter, Gavin Thurston, Adrian L. Harris. (2010) Expression of Vascular Notch Ligand Delta-Like 4 and Inflammatory Markers in Breast Cancer. The American Journal of Pathology 176:4, 2019-2028
CrossRef397
Mackenzie C. McGee, J. Blair Hamner, Regan F. Williams, Shannon F. Rosati, Thomas L. Sims, Catherine Y. Ng, M. Waleed Gaber, Christopher Calabrese, Jianrong Wu, Amit C. Nathwani, Christopher Duntsch, Thomas E. Merchant, Andrew M. Davidoff. (2010) Improved Intratumoral Oxygenation Through Vascular Normalization Increases Glioma Sensitivity to Ionizing Radiation. International Journal of Radiation Oncology*Biology*Physics 76:5, 1537-1545
CrossRef398
Rupert Bartsch, Reinhard Ziebermayr, Christoph C. Zielinski, Guenther G. Steger. (2010) Triple-negative breast cancer. Wiener Medizinische Wochenschrift 160:7-8, 174-181
CrossRef399
Arvinder Bhinder, Sarah Carothers, Bhuvaneswari Ramaswamy. (2010) Antiangiogenesis Therapy in Breast Cancer. Current Breast Cancer Reports 2:1, 4-15
CrossRef400
Anil Bagri, Hosein Kouros-Mehr, Kevin G. Leong, Greg D. Plowman. (2010) Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale. Trends in Molecular Medicine 16:3, 122-132
CrossRef401
Jennifer Delli Carpini, Amer K. Karam, Leslie Montgomery. (2010) Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 13:1, 43-58
CrossRef402
Tamás Nagykálnai, László Landherr, Edina Mészáros. (2010) Lehetőségek anthracyclin- és/vagy taxánkezelések után progrediáló emlőrákban. Magyar Onkológia 54:1, 9-16
CrossRef403
John P. Diaz, William P. Tew, Oliver Zivanovic, Jason Konner, Paul J. Sabbatini, Lisa A. dos Santos, Nadeem R. Abu-Rustum, Dennis S. Chi, Carol Aghajanian, Richard R. Barakat. (2010) Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma. Gynecologic Oncology 116:3, 335-339
CrossRef404
Youssef Bennis, Benjamin Guillet, Christophe Curti, Pascale Pisano. (2010) Intérêts thérapeutiques des médicaments antiangiogéniques disponibles en cancérologie. Thérapie 65:2, 95-105
CrossRef405
Serena T. Wong, Deborah Toppmeyer. (2010) Adjuvant Chemotherapy for Early Stage Breast Cancer: Current Trends and Future Directions. Current Breast Cancer Reports 2:1, 16-24
CrossRef406
Omer Dizdar, Kadri Altundag. (2010) Current and emerging treatment options in triple-negative breast cancer. Oncology Reviews 4:1, 5-13
CrossRef407
Kristen Ganjoo, Charlotte Jacobs. (2010) Antiangiogenesis agents in the treatment of soft tissue sarcomas. Cancer 116:5, 1177-1183
CrossRef408
Anne Katrin Berger, Thomas Herrmann. (2010) „Targeted therapies“ in der Behandlung solider Tumoren. Onkopipeline 3:1, 48-51
CrossRef409
Serena Di Cosimo, José Baselga. (2010) Management of breast cancer with targeted agents: importance of heterogenicity. Nature Reviews Clinical Oncology 7:3, 139-147
CrossRef410
Anwar R. Padhani, Aftab Alam Khan. (2010) Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy. Targeted Oncology 5:1, 39-52
CrossRef411
J-M Lee, G A Sarosy, C M Annunziata, N Azad, L Minasian, H Kotz, J Squires, N Houston, E C Kohn. (2010) Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. British Journal of Cancer 102:3, 495-499
CrossRef412
N C Tebbutt, M M Cummins, T Sourjina, A Strickland, G Van Hazel, V Ganju, D Gibbs, M Stockler, V Gebski, J Zalcberg. (2010) Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. British Journal of Cancer 102:3, 475-481
CrossRef413
Emanuel Raschi, Valentina Vasina, Maria Grazia Ursino, Giuseppe Boriani, Andrea Martoni, Fabrizio De Ponti. (2010) Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. Pharmacology & Therapeutics 125:2, 196-218
CrossRef414
Yihai Cao. (2010) Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nature Reviews Drug Discovery 9:2, 107-115
CrossRef415
Yolanda Fernández, Juan Cueva, Andrés G. Palomo, Manuel Ramos, Ana de Juan, Lourdes Calvo, Jesús García-Mata, Paula García-Teijido, Ignacio Peláez, Laura García-Estévez. (2010) Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treatment Reviews 36:1, 33-42
CrossRef416
Tobias Bäuerle, Sönke Bartling, Martin Berger, Annette Schmitt-Gräff, Heidegard Hilbig, Hans-Ulrich Kauczor, Stefan Delorme, Fabian Kiessling. (2010) Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis. European Journal of Radiology 73:2, 280-287
CrossRef417
Ramachandran Venkitaraman. (2010) Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features. Expert Review of Anticancer Therapy 10:2, 199-207
CrossRef418
Ying-Kiat Zee, James P. B. O'Connor, Geoff J. M. Parker, Alan Jackson, Andrew R. Clamp, M. Ben Taylor, Noel W. Clarke, Gordon C. Jayson. (2010) Imaging angiogenesis of genitourinary tumors. Nature Reviews Urology 7:2, 69-82
CrossRef419
, Paula Manchon, Josep M. Borràs, Tàrsila Ferro, Josep Alfons Espinàs. (2010) Breast cancer OncoGuia. Clinical and Translational Oncology 12:2, 113-137
CrossRef420
E. A. Perez, D. W. Hillman, T. Dentchev, N. A. Le-Lindqwister, L. H. Geeraerts, T. R. Fitch, H. Liu, D. L. Graham, S. P. Kahanic, H. M. Gross, T. A. Patel, F. M. Palmieri, A. C. Dueck. (2010) North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. Annals of Oncology 21:2, 269-274
CrossRef421
Francesco Recchia, Ferdinando Di Orio, Giampiero Candeloro, Gabriele Guerriero, Juan Piazze, Silvio Rea. (2010) Maintenance immunotherapy in recurrent ovarian cancer: Long term follow-up of a phase II study. Gynecologic Oncology 116:2, 202-207
CrossRef422
Jennifer Wheler, Apostolia M. Tsimberidou, Stacy Moulder, Massimo Cristofanilli, David Hong, Aung Naing, Raminder Pathak, Suyu Liu, Lei Feng, Razelle Kurzrock. (2010) Clinical Outcomes of Patients With Breast Cancer in a Phase I Clinic: The M. D. Anderson Cancer Center Experience. Clinical Breast Cancer 10:1, 46-51
CrossRef423
Angelos K. Koutras, George Fountzilas, Thomas Makatsoris, Stavros Peroukides, Haralabos P. Kalofonos. (2010) Bevacizumab in the treatment of breast cancer. Cancer Treatment Reviews 36:1, 75-82
CrossRef424
Keun Seok Lee, Jungsil Ro, Eun Sook Lee, Han Sung Kang, Seok Won Kim, Byung-Ho Nam, Youngmee Kwon, Eun-A Kim, Kyung Hwan Shin. (2010) Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: a phase II trial. Investigational New Drugs 28:1, 83-90
CrossRef425
Tristin Abair, Kristin Garcia, Timothy Quill. (2010) The 2009 San Antonio Breast Cancer Symposium. Clinical Breast Cancer 10:1, 19-26
CrossRef426
M. Schmidt, M. E. Scheulen, C. Dittrich, P. Obrist, N. Marschner, L. Dirix, M. Schmidt, D. Ruttinger, M. Schuler, C. Reinhardt, A. Awada. (2010) An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Annals of Oncology 21:2, 275-282
CrossRef427
Jetske Ruiterkamp, Adri C. Voogd, Koop Bosscha, Vivianne C. G. Tjan-Heijnen, Miranda F. Ernst. (2010) Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature. Breast Cancer Research and Treatment 120:1, 9-16
CrossRef428
Verena Bossung, Nadia Harbeck. (2010) Angiogenesis inhibitors in the management of breast cancer. Current Opinion in Obstetrics and Gynecology 22:1, 79-86
CrossRef429
Yeon Hee Park, Seung Tae Kim, Eun Yoon Cho, Yoon La Choi, Oh-Nam Ok, Hae Jin Baek, Jeong Eon Lee, Seok Jin Nam, Jung-Hyun Yang, Won Park, Doo Ho Choi, Seung Jae Huh, Jin Seok Ahn, Young-Hyuck Im. (2010) A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?. Breast Cancer Research and Treatment 119:3, 653-661
CrossRef430
Zachary A. Knight, Henry Lin, Kevan M. Shokat. (2010) Targeting the cancer kinome through polypharmacology. Nature Reviews Cancer 10:2, 130-137
CrossRef431
Hua Yang, Kun Yang, Jian-Kun Hu, Hong Tang, Bo Zhang, Zhi-Xin Chen, You-Juan Wang, Jia-Ping Chen. (2010) Eukaryotic expression of extracellular ligand binding domains of murine Tie-2 and its anti-angiogenesis effect in SGC-7901 cell lines. Journal of Gastroenterology and Hepatology 25:2, 345-351
CrossRef432
Joseph A. Sparano, Gabriel N. Hortobagyi, Julie R. Gralow, Edith A. Perez, Robert L. Comis. (2010) Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization. Breast Cancer Research and Treatment 119:3, 511-527
CrossRef433
Denise A. Yardley. (2010) Visceral Disease in Patients With Metastatic Breast Cancer: Efficacy and Safety of Treatment With Ixabepilone and Other Chemotherapeutic Agents. Clinical Breast Cancer 10:1, 64-73
CrossRef434
Napoleone Ferrara. (2010) Pathways mediating VEGF-independent tumor angiogenesis. Cytokine & Growth Factor Reviews 21:1, 21-26
CrossRef435
G Mickisch, M Gore, B Escudier, G Procopio, S Walzer, M Nuijten. (2010) Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib. British Journal of Cancer 102:1, 80-86
CrossRef436
N Murukesh, C Dive, G C Jayson. (2010) Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. British Journal of Cancer 102:1, 8-18
CrossRef437
A.A. Kotsori, S. Dolly, A. Sheri, M. Parton, N. Shaunak, S. Ashley, G. Walsh, S. Johnston, I.E. Smith. (2010) Is Capecitabine Efficacious in Triple Negative Metastatic Breast Cancer?. Oncology 79:5-6, 331-336
CrossRef438
Neville Davidson. (2010) The role of nab™-paclitaxel in managing metastatic breast cancer: a report of three cases. European Journal of Cancer Supplements 8:1, 11-18
CrossRef439
Lyndsay J. Willmott, John P. Fruehauf. (2010) Targeted Therapy in Ovarian Cancer. Journal of Oncology 2010, 1-9
CrossRef440
Andrew R. Reynolds. (2010) Potential Relevance of Bell-Shaped and U-Shaped Dose-Responses for the Therapeutic Targeting of Angiogenesis in Cancer. Dose-Response 8:3, 253-284
CrossRef441
L.I. Chap. (2010) Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation. Breast Diseases: A Year Book Quarterly 21:1, 78-79
CrossRef442
Michael Medinger, Natalie Fischer, Alexandar Tzankov. (2010) Vascular Endothelial Growth Factor-Related Pathways in Hemato-Lymphoid Malignancies. Journal of Oncology 2010, 1-13
CrossRef443
Philipp Harter, Felix Hilpert, Sven Mahner, Florian Heitz, Jacobus Pfisterer, Andreas du Bois. (2010) Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. Expert Review of Anticancer Therapy 10:1, 81-88
CrossRef444
Javier Cortes, Cristina Saura. (2010) Nanoparticle albumin-bound (nab™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer. European Journal of Cancer Supplements 8:1, 1-10
CrossRef445
Shari B Goldfarb, Tiffany A Traina, Maura N Dickler. (2010) Bevacizumab for advanced breast cancer. Women's Health 6:1, 17-25
CrossRef446
Nam Hee Kim, Hye Jin Jung, Futoshi Shibasaki, Ho Jeong Kwon. (2010) NBBA, a synthetic small molecule, inhibits TNF-α-induced angiogenesis by suppressing the NF-κB signaling pathway. Biochemical and Biophysical Research Communications 391:3, 1500-1505
CrossRef447
Andrew X Zhu, Jeffrey A Meyerhardt, Lawrence S Blaszkowsky, Avinash R Kambadakone, Alona Muzikansky, Hui Zheng, Jeffrey W Clark, Thomas A Abrams, Jennifer A Chan, Peter C Enzinger, Pankaj Bhargava, Eunice L Kwak, Jill N Allen, Sanjay R Jain, Keith Stuart, Kerry Horgan, Susan Sheehan, Charles S Fuchs, David P Ryan, Dushyant V Sahani. (2010) Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. The Lancet Oncology 11:1, 48-54
CrossRef448
Ingrid A. Boere, Paul Hamberg, Stefan Sleijfer. (2010) It takes two to tango: Combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factorâvascular endothelial growth factor receptor pathway in patients with solid malignancies. Cancer Science 101:1, 7-15
CrossRef449
Austin Duffy, Shivaani Kummar. (2010) Metastatic Pancreatic Adenocarcinoma: Current Standards, Future Directions. American Journal of Therapeutics 17:1, 79-85
CrossRef450
Michael S. Gordon, David S. Mendelson, Gerry Kato. (2010) Tumor angiogenesis and novel antiangiogenic strategies. International Journal of CancerNA-NA
CrossRef451
Sergio Bracarda, Alexander M.M. Eggermont, Jan Samuelsson. (2010) Redefining the role of interferon in the treatment of malignant diseases. European Journal of Cancer 46:2, 284-297
CrossRef452
Bettina Reismüller, Amedeo A. Azizi, Andreas Peyrl, Monika Heinrich, Mariella Gruber-Olipitz, Doris Luckner, Klara Vergesslich Rothschild, Irene Slavc. (2010) Feasibility and tolerability of bevacizumab in children with primary CNS tumors. Pediatric Blood & Cancern/a-n/a
CrossRef453
Hassane Izzedine, Christophe Massard, Jean Philippe Spano, François Goldwasser, David Khayat, Jean Charles Soria. (2010) VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. European Journal of Cancer 46:2, 439-448
CrossRef454
Mathew P. Leese, Fabrice Jourdan, Meriel R. Kimberley, Gyles E. Cozier, Nethaji Thiyagarajan, Chloe Stengel, Sandra Regis-Lydi, Paul A. Foster, Simon P. Newman, K. Ravi Acharya, Eric Ferrandis, Atul Purohit, Michael J. Reed, Barry V. L. Potter. (2010) Chimeric microtubule disruptors. Chemical Communications 46:17, 2907
CrossRef455
Stephen M. Keefe, Angela DeMichele. (2010) The Expanding Role of Bevacizumab in the Treatment of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. Current Oncology Reports 12:1, 22-25
CrossRef456
Sally Greenberg, Hope S. Rugo. (2010) Triple-Negative Breast Cancer. The Cancer Journal 16:1, 33-38
CrossRef457
Steven J. Isakoff. (2010) Triple-Negative Breast Cancer. The Cancer Journal 16:1, 53-61
CrossRef458
E. D. Saad, A. Katz, P. M. Hoff, M. Buyse. (2010) Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Annals of Oncology 21:1, 7-12
CrossRef459
R. Sikorski, B. Yao. (2009) Parallel Paths to Predictive Biomarkers in Oncology: Uncoupling of Emergent Biomarker Development and Phase III Trial Execution. Science Translational Medicine 1:10, 10ps11-10ps11
CrossRef460
Alexandru Eniu, G. Morar-Bolba. (2009) Best of breast cancer – ASCO 2009. memo - Magazine of European Medical Oncology 2:4, 223-227
CrossRef461
O. Gluz, C. Liedtke, N. Gottschalk, L. Pusztai, U. Nitz, N. Harbeck. (2009) Triple-negative breast cancer--current status and future directions. Annals of Oncology 20:12, 1913-1927
CrossRef462
Brigitte Rack, Volkmar Müller, Sabine Kasimir-Bauer, Christian Schindlbeck, Wolfgang Janni. (2009) Minimal residual cancer and its clinical relevance. Current Breast Cancer Reports 1:4, 198-206
CrossRef463
Sherry X Yang. (2009) Bevacizumab and breast cancer: current therapeutic progress and future perspectives. Expert Review of Anticancer Therapy 9:12, 1715-1725
CrossRef464
Chad M Barnett. (2009) Survival Data of Patients with Anthracycline- or Taxane-Pretreated or Resistant Metastatic Breast Cancer. Pharmacotherapy 29:12, 1482-1490
CrossRef465
Yongping Crawford, Napoleone Ferrara. (2009) Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends in Pharmacological Sciences 30:12, 624-630
CrossRef466
Fang Guo, Xiaodong Xie, Zhaozhe Liu. (2009) The application of Meta-analysis in the latest comprehensive treatment of breast cancer. The Chinese-German Journal of Clinical Oncology 8:12, 729-733
CrossRef467
Seema Harichand-Herdt, Suresh S. Ramalingam. (2009) Gender-Associated Differences in Lung Cancer: Clinical Characteristics and Treatment Outcomes in Women. Seminars in Oncology 36:6, 572-580
CrossRef468
Enrique Lerma, Agusti Barnadas, Jaime Prat. (2009) Triple Negative Breast Carcinomas. Applied Immunohistochemistry & Molecular Morphology 17:6, 483-494
CrossRef469
Carey K. Anders, Lisa A. Carey. (2009) Biology, Metastatic Patterns, and Treatment of Patients With Triple-Negative Breast Cancer. Clinical Cancer Reviews 3:1, 39-47
CrossRef470
Hossein Borghaei, Mitchell R. Smith, Kerry S. Campbell. (2009) Immunotherapy of cancer. European Journal of Pharmacology 625:1-3, 41-54
CrossRef471
David R. Spigel, F Anthony Greco, John D. Zubkus, Patrick B. Murphy, Ruben A. Saez, Cindy Farley, Denise A. Yardley, Howard A. Burris, John D. Hainsworth. (2009) Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer. Journal of Thoracic Oncology 4:12, 1555-1560
CrossRef472
Roisin Connolly, Vered Stearns. (2009) The role of pharmacogenetics in selection of breast cancer treatment. Current Breast Cancer Reports 1:4, 190-197
CrossRef473
Akihiro Tamiya, Kentaro Yamazaki, Narikazu Boku, Nozomu Machida, Takashi Kojima, Keisei Taku, Hirofumi Yasui, Akira Fukutomi, Shuichi Hironaka, Yusuke Onozawa. (2009) Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients. International Journal of Clinical Oncology 14:6, 513-517
CrossRef474
Julia Aigner, Andreas Schneeweiss. (2009) Systemtherapie des Mammakarzinoms. Onkopipeline 2:4, 171-184
CrossRef475
Tony S. K. Mok, Suresh S. Ramalingam. (2009) Maintenance therapy in nonsmall-cell lung cancer. Cancer 115:22, 5143-5154
CrossRef476
David J. Gallagher, Matthew I. Milowsky, Alexia Iasonos, Fernando C. Maluf, Paul Russo, Guido Dalbagni, Machele S. Donat, Mary G. Boyle, Junting Zheng, Jamie Riches, Dean F. Bajorin. (2009) Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma. Cancer 115:22, 5193-5201
CrossRef477
A. P. Marin, A. R. Sanchez, E. E. Arranz. (2009) Nasal septum perforation in a breast cancer patient treated with bevacizumab. Annals of Oncology 20:11, 1901-1902
CrossRef478
Carlos A Castaneda, Henry L Gomez. (2009) Pazopanib: an antiangiogenic drug in perspective. Future Oncology 5:9, 1335-1348
CrossRef479
John Mackey, Karen Gelmon, Miguel Martin, Nicole McCarthy, Tamas Pinter, Mathieu Rupin, Hagop Youssoufian. (2009) TRIO-012: A Multicenter, Multinational, Randomized, Double-Blind Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally Recurrent or Metastatic Breast Cancer. Clinical Breast Cancer 9:4, 258-261
CrossRef480
S. Beslija, J. Bonneterre, H. J. Burstein, V. Cocquyt, M. Gnant, V. Heinemann, J. Jassem, W. J. Kostler, M. Krainer, S. Menard, T. Petit, L. Petruzelka, K. Possinger, P. Schmid, E. Stadtmauer, M. Stockler, S. Van Belle, C. Vogel, N. Wilcken, C. Wiltschke, C. C. Zielinski, H. Zwierzina, . (2009) Third consensus on medical treatment of metastatic breast cancer. Annals of Oncology 20:11, 1771-1785
CrossRef481
(2009) Cancer du sein métastatique. Oncologie 11:11, 552-588
CrossRef482
Peter Barrett-Lee, François-Clément Bidard, Jean-Yves Pierga. (2009) Contemporary issues and the potential uses of capecitabine in metastatic breast cancer. Cancer Treatment Reviews 35:7, 582-589
CrossRef483
Francesca Greco, María J. Vicent. (2009) Combination therapy: Opportunities and challenges for polymer–drug conjugates as anticancer nanomedicines. Advanced Drug Delivery Reviews 61:13, 1203-1213
CrossRef484
Ting-Ting Hung, Jun-Yi Wu, Ju-Fang Liu, Hung-Chi Cheng. (2009) Epitope analysis of the rat dipeptidyl peptidase IV monoclonal antibody 6A3 that blocks pericellular fibronectin-mediated cancer cell adhesion. FEBS Journal 276:22, 6548-6559
CrossRef485
I.E. Smith. (2009) Targeting HER2 in the adjuvant setting: Dealing with new standards and with open questions. The Breast 18, S146-S149
CrossRef486
Alfonso Sánchez-Muñoz, Elisabeth Pérez-Ruiz, Begoña Jiménez, Nuria Ribelles, Antonia Márquez, Isabel García-Ríos, Emilio Alba Conejo. (2009) Targeted therapy of metastatic breast cancer. Clinical and Translational Oncology 11:10, 643-650
CrossRef487
Junichi Kurebayashi. (2009) Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics. Breast Cancer 16:4, 275-280
CrossRef488
Dimitrios H Roukos, Andreas Tzakos, George Zografos. (2009) Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer. Expert Review of Anticancer Therapy 9:10, 1413-1416
CrossRef489
S. F. Dent. (2009) The role of VEGF in triple-negative breast cancer: where do we go from here?. Annals of Oncology 20:10, 1615-1617
CrossRef490
T.H. Oude Munnink, W.B. Nagengast, A.H. Brouwers, C.P. Schröder, G.A. Hospers, M.N. Lub-de Hooge, E. van der Wall, P.J. van Diest, E.G.E. de Vries. (2009) Molecular imaging of breast cancer. The Breast 18, S66-S73
CrossRef491
Jennifer Specht, Julie R. Gralow. (2009) Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer. Seminars in Radiation Oncology 19:4, 222-228
CrossRef492
B. K. Linderholm, H. Hellborg, U. Johansson, G. Elmberger, L. Skoog, J. Lehtio, R. Lewensohn. (2009) Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Annals of Oncology 20:10, 1639-1646
CrossRef493
Tobias Bäuerle, Wolfhard Semmler. (2009) Imaging response to systemic therapy for bone metastases. European Radiology 19:10, 2495-2507
CrossRef494
Robert S. Kerbel. (2009) Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer. The Breast 18, S41-S47
CrossRef495
Jerry Y. Hsu, Heather A. Wakelee. (2009) Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor. BioDrugs 23:5, 289-304
CrossRef496
R. Greil, M. Moik, R. Reitsamer, S. Ressler, M. Stoll, K. Namberger, C. Menzel, B. Mlineritsch. (2009) Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study. European Journal of Surgical Oncology (EJSO) 35:10, 1048-1054
CrossRef497
Sharon L. Sanborn, Joseph Gibbons, Smitha Krishnamurthi, Joanna M. Brell, Afshin Dowlati, Joseph A. Bokar, Charles Nock, Nancy Horvath, Jacob Bako, Scot C. Remick, Matthew M. Cooney. (2009) Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors. Investigational New Drugs 27:5, 453-460
CrossRef498
Hans Petter Eikesdal, Raghu Kalluri. (2009) Drug resistance associated with antiangiogenesis therapy. Seminars in Cancer Biology 19:5, 310-317
CrossRef499
F. Cardoso, P. L. Bedard, E. P. Winer, O. Pagani, E. Senkus-Konefka, L. J. Fallowfield, S. Kyriakides, A. Costa, T. Cufer, K. S. Albain, . (2009) International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy. JNCI Journal of the National Cancer Institute 101:17, 1174-1181
CrossRef500
Patrick G Morris, Clifford A Hudis. (2009) Personalizing therapy for metastatic breast cancer. Expert Review of Anticancer Therapy 9:9, 1223-1226
CrossRef501
Gregory P. Sfakianos, T. Michael Numnum, Caitlin B. Halverson, Deepa Panjeti, James E. Kendrick, J. Michael Straughn. (2009) The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: A retrospective cohort study. Gynecologic Oncology 114:3, 424-426
CrossRef502
Axel Grothey, Evanthia Galanis. (2009) Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nature Reviews Clinical Oncology 6:9, 507-518
CrossRef503
Julia Wilkerson, Tito Fojo. (2009) Progression-Free Survival Is Simply a Measure of a Drug’s Effect While Administered and Is Not a Surrogate for Overall Survival. The Cancer Journal 15:5, 379-385
CrossRef504
J. -M. Halimi, M. Azizi, G. Bobrie, O. Bouché, G. Deray, G. Guetz, T. Lecomte, B. Levy, J. -J. Mourad, D. Nochy, S. Oudard, P. Rieu, D. Sahali. (2009) Effets vasculaires et rénaux des médicaments anti-angiogéniques: recommandations françaises pour la pratique. Oncologie 11:9-10, 476-489
CrossRef505
Sara A Hurvitz, Richard S Finn. (2009) What’s positive about ‘triple-negative’ breast cancer?. Future Oncology 5:7, 1015-1025
CrossRef506
Fatma M. Taha, Ahmed A. Zeeneldin, Amani M. Helal, Ayman A. Gaber, Yasser A. Sallam, Hanan Ramadan, Manar M. Moneer. (2009) Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancer. Clinical Biochemistry 42:13-14, 1420-1426
CrossRef507
S.J. Dawson, E. Provenzano, C. Caldas. (2009) Triple negative breast cancers: Clinical and prognostic implications. European Journal of Cancer 45, 27-40
CrossRef508
E-M Boneberg, D F Legler, M M Hoefer, C Öhlschlegel, H Steininger, L Füzesi, G M Beer, V Dupont-Lampert, F Otto, H-J Senn, G Fürstenberger. (2009) Angiogenesis and lymphangiogenesis are downregulated in primary breast cancer. British Journal of Cancer 101:4, 605-614
CrossRef509
T. Fojo, C. Grady. (2009) How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question. JNCI Journal of the National Cancer Institute 101:15, 1044-1048
CrossRef510
Alvaro Moreno-Aspitia, Edith A. Perez. (2009) Anthracycline- and/or taxane-resistant breast cancer: Results of a literature review to determine the clinical challenges and current treatment trends. Clinical Therapeutics 31:8, 1619-1640
CrossRef511
Sumanta Kumar Pal, Joanne Mortimer. (2009) Triple-negative breast cancer: Novel therapies and new directions. Maturitas 63:4, 269-274
CrossRef512
Helen X. Chen, Jessica N. Cleck. (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nature Reviews Clinical Oncology 6:8, 465-477
CrossRef513
Yuval Shaked, Emile E. Voest. (2009) Bone marrow derived cells in tumor angiogenesis and growth: are they the good, the bad or the evil?. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1796:1, 1-4
CrossRef514
J.M.L. Roodhart, M.H.G. Langenberg, L.G.M. Daenen, E.E. Voest. (2009) Translating preclinical findings of (endothelial) progenitor cell mobilization into the clinic; from bedside to bench and back. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1796:1, 41-49
CrossRef515
Serena T Wong, Susan Goodin. (2009) Overcoming Drug Resistance in Patients with Metastatic Breast Cancer. Pharmacotherapy 29:8, 954-965
CrossRef516
Johnny Kao, Stuart Packer, Ha Linh Vu, Myron E. Schwartz, Max W. Sung, Richard G. Stock, Yeh-Chi Lo, Delphine Huang, Shu-Hsia Chen, Jamie A. Cesaretti. (2009) Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases. Cancer 115:15, 3571-3580
CrossRef517
Luigi Coltelli, Giacomo Allegrini, Paola Orlandi, Nicola Giuntini, Greta Alì, Anna Fioravanti, Eleonora Bona, Maria Teresa Barletta, Gabriella Fontanini, Mario Del Tacca, Romano Danesi, Alfredo Falcone, Guido Bocci. (2009) Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. Pharmacogenomics 10:8, 1225-1229
CrossRef518
N Tubiana-Mathieu, P Bougnoux, D Becquart, A Chan, P-F Conte, F Majois, M Espie, M Morand, N Vaissiere, G Villanova. (2009) All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial. British Journal of Cancer 101:2, 232-237
CrossRef519
Gerald M Higa, Jame Abraham. (2009) Biological mechanisms of bevacizumab-associated adverse events. Expert Review of Anticancer Therapy 9:7, 999-1007
CrossRef520
Bonnie J. Nieves, Patricia A. D'Amore, Brad A. Bryan. (2009) The function of vascular endothelial growth factor. BioFactors 35:4, 332-337
CrossRef521
Andrew S. Chi, Andrew D. Norden, Patrick Y. Wen. (2009) Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics 6:3, 513-526
CrossRef522
Dimosthenis Ziogas, Dimitrios H. Roukos. (2009) Genetics and Personal Genomics for Personalized Breast Cancer Surgery: Progress and Challenges in Research and Clinical Practice. Annals of Surgical Oncology 16:7, 1771-1782
CrossRef523
Vivek Roy, Edith A. Perez. (2009) Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways. Breast Cancer Research and Treatment 116:1, 31-38
CrossRef524
I Chau, D Cunningham. (2009) Treatment in advanced colorectal cancer: what, when and how?. British Journal of Cancer 100:11, 1704-1719
CrossRef525
Leslie A. Fecher, Ravi K. Amaravadi, Lynn M. Schuchter, Keith T. Flaherty. (2009) Drug Targeting of Oncogenic Pathways in Melanoma. Hematology/Oncology Clinics of North America 23:3, 599-618
CrossRef526
Emma S Rennel, Steven J Harper, David O Bates. (2009) Therapeutic potential of manipulating VEGF splice isoforms in oncology. Future Oncology 5:5, 703-712
CrossRef527
Sanjaykumar Hapani, David Chu, Shenhong Wu. (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. The Lancet Oncology 10:6, 559-568
CrossRef528
J. Gligorov, D. Azria, Y. Belkacemi, M. Spielmann, M. Namer. (2009) La recherche clinique dans le domaine du cancer du sein: état des lieux et perspectives. Oncologie 11:6, 319-324
CrossRef529
Rakesh K. Jain, Dan G. Duda, Christopher G. Willett, Dushyant V. Sahani, Andrew X. Zhu, Jay S. Loeffler, Tracy T. Batchelor, A. Gregory Sorensen. (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nature Reviews Clinical Oncology 6:6, 327-338
CrossRef530
Shadfar Bahri, Jeon-Hor Chen, Rita S. Mehta, Philip M. Carpenter, Ke Nie, Soon-Young Kwon, Hon J. Yu, Orhan Nalcioglu, Min-Ying Su. (2009) Residual Breast Cancer Diagnosed by MRI in Patients Receiving Neoadjuvant Chemotherapy with and Without Bevacizumab. Annals of Surgical Oncology 16:6, 1619-1628
CrossRef531
Kelly L. Snider, Michael L. Maitland. (2009) Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Targeted Oncology 4:2, 67-76
CrossRef532
A. d’Onofrio, A. Gandolfi, A. Rocca. (2009) The dynamics of tumour-vasculature interaction suggests low-dose, time-dense anti-angiogenic schedulings. Cell Proliferation 42:3, 317-329
CrossRef533
Ronan J. Kelly, Bertrand Billemont, Olivier Rixe. (2009) Renal toxicity of targeted therapies. Targeted Oncology 4:2, 121-133
CrossRef534
Chad A. Livasy. (2009) Triple-Negative Breast Carcinoma. Surgical Pathology Clinics 2:2, 247-261
CrossRef535
Peter J. Frederick, J. Michael Straughn, Ronald D. Alvarez, Donald J. Buchsbaum. (2009) Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer. Gynecologic Oncology 113:3, 384-390
CrossRef536
Edward T.H. Yeh, Courtney L. Bickford. (2009) Cardiovascular Complications of Cancer Therapy. Journal of the American College of Cardiology 53:24, 2231-2247
CrossRef537
David M. Jackman. (2009) Current Options for Systemic Therapy in Mesothelioma. Seminars in Thoracic and Cardiovascular Surgery 21:2, 154-158
CrossRef538
Roberta Ferraldeschi, Paul Lorigan. (2009) Targeting angiogenesis in melanoma. Expert Review of Dermatology 4:3, 237-248
CrossRef539
Hernán Cortés-Funes. (2009) The role of antiangiogenesis therapy: Bevacizumab and beyond. Clinical and Translational Oncology 11:6, 349-355
CrossRef540
A. Moreno-Aspitia, E. A. Perez. (2009) Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane. Mayo Clinic Proceedings 84:6, 533-545
CrossRef541
M. Chivukula, A. Brufsky, N. E. Davidson. (2009) Small Beginnings: Do They Matter? The Importance of Lymphovascular Invasion in Early Breast Cancer. JNCI Journal of the National Cancer Institute 101:10, 698-699
CrossRef542
Konstantin J. Dedes, Klazien Matter-Walstra, Matthias Schwenkglenks, Bernhard C. Pestalozzi, Daniel Fink, Peter Brauchli, Thomas D. Szucs. (2009) Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation. European Journal of Cancer 45:8, 1397-1406
CrossRef543
Andrea Nicolini, Angelo Carpi. (2009) Immune manipulation of advanced breast cancer: An interpretative model of the relationship between immune system and tumor cell biology. Medicinal Research Reviews 29:3, 436-471
CrossRef544
Colin R Lindsay, Iain RJ MacPherson, Jim Cassidy. (2009) Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Future Oncology 5:4, 421-432
CrossRef545
Manuela Schmidinger, Christoph C. Zielinski. (2009) Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy. Cancer Treatment Reviews 35:3, 289-296
CrossRef546
Jens Soltau, Joachim Drevs. (2009) Mode of action and clinical impact of VEGF signaling inhibitors. Expert Review of Anticancer Therapy 9:5, 649-662
CrossRef547
Camillo Porta, Cezary Szczylik. (2009) Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treatment Reviews 35:3, 297-307
CrossRef548
H. Izzedine, S. Ederhy, F. Goldwasser, J. C. Soria, G. Milano, A. Cohen, D. Khayat, J. P. Spano. (2009) Management of hypertension in angiogenesis inhibitor-treated patients. Annals of Oncology 20:5, 807-815
CrossRef549
F. Cardoso, M. Castiglione, . (2009) Locally recurrent or metastatic breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 20:Supplement 4, iv15-iv18
CrossRef550
C. Dreyer, E. Raymond, S. Faivre. (2009) Les thérapies ciblées et leurs indications dans les tumeurs solides. La Revue de Médecine Interne 30:5, 416-424
CrossRef551
Johanna A. Joyce, Jeffrey W. Pollard. (2009) Microenvironmental regulation of metastasis. Nature Reviews Cancer 9:4, 239-252
CrossRef552
Ernest S. Han, Paul Lin, Mark Wakabayashi. (2009) Current Status on Biologic Therapies in the Treatment of Epithelial Ovarian Cancer. Current Treatment Options in Oncology 10:1-2, 54-66
CrossRef553
H J Mauceri, M A Beckett, H Liang, H G Sutton, S Pitroda, E Galka, E Efimova, T Darga, N N Khodarev, C R King, M C Posner, S Hellman, D W Kufe, R R Weichselbaum. (2009) Translational strategies exploiting TNF-α that sensitize tumors to radiation therapy. Cancer Gene Therapy 16:4, 373-381
CrossRef554
Faina Gurevich, Mark A. Perazella. (2009) Renal Effects of Anti-angiogenesis Therapy: Update for the Internist. The American Journal of Medicine 122:4, 322-328
CrossRef555
Surabhi Amar, Vivek Roy, Edith A. Perez. (2009) Treatment of metastatic breast cancer: looking towards the future. Breast Cancer Research and Treatment 114:3, 413-422
CrossRef556
Andrew R Reynolds, Ian R Hart, Alan R Watson, Jonathan C Welti, Rita G Silva, Stephen D Robinson, Georges Da Violante, Morgane Gourlaouen, Mishal Salih, Matt C Jones, Dylan T Jones, Garry Saunders, Vassiliki Kostourou, Françoise Perron-Sierra, Jim C Norman, Gordon C Tucker, Kairbaan M Hodivala-Dilke. (2009) Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nature Medicine 15:4, 392-400
CrossRef557
Puja Gaur, Debashish Bose, Shaija Samuel, Lee M. Ellis. (2009) Targeting Tumor Angiogenesis. Seminars in Oncology 36, S12-S19
CrossRef558
I. E. Haines, I. Olver. (2009) Are guidelines on use of colony-stimulating factors in solid cancers flawed?. Internal Medicine Journal 39:4, 259-262
CrossRef559
Krishnansu S. Tewari, Bradley J. Monk. (2009) Recent Achievements and Future Developments in Advanced and Recurrent Cervical Cancer: Trials of the Gynecologic Oncology Group. Seminars in Oncology 36:2, 170-180
CrossRef560
Richard S Finn, Andrew X Zhu. (2009) Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Review of Anticancer Therapy 9:4, 503-509
CrossRef561
Christian Jackisch. (2009) Role of cytotoxics in combination with targeted agents. European Journal of Cancer Supplements 7:1, 19-22
CrossRef562
Efstathios Kastritis, Andreas Charidimou, Andreas Varkaris, Meletios A. Dimopoulos. (2009) Targeted therapies in multiple myeloma. Targeted Oncology 4:1, 23-36
CrossRef563
Alessandra Balduzzi, Emilia Montagna, Vincenzo Bagnardi, Rosalba Torrisi, Francesco Bertolini, Patrizia Mancuso, Eloise Scarano, Giuseppe Viale, Paolo Veronesi, Anna Cardillo, Laura Orlando, Aron Goldhirsch, Marco Colleoni. (2009) Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features. Anti-Cancer Drugs 20:3, 197-203
CrossRef564
Vasiliki Michalaki, Spyridon Gennatas, Konstantine Gennatas. (2009) Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results. Anti-Cancer Drugs 20:3, 204-207
CrossRef565
C. Lance Cowey, W. Kimryn Rathmell. (2009) VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy. Current Oncology Reports 11:2, 94-101
CrossRef566
Dimiter V Tassev, Nai-Kong V Cheung. (2009) Monoclonal antibody therapies for solid tumors. Expert Opinion on Biological Therapy 9:3, 341-353
CrossRef567
PierFranco Conte, Valentina Guarneri. (2009) Triple-negative breast cancer: current management and future options. European Journal of Cancer Supplements 7:1, 14-18
CrossRef568
Parham Khosravi Shahi, Alicia Soria Lovelle, Gumersindo Pérez Manga. (2009) Tumoral angiogenesis and breast cancer. Clinical and Translational Oncology 11:3, 138-142
CrossRef569
K. Tipples, A. Robinson. (2009) Optimising Care of Elderly Breast Cancer Patients: a Challenging Priority. Clinical Oncology 21:2, 118-130
CrossRef570
Diane L Reidy, Laura H Tang, Leonard B Saltz. (2009) Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors. Nature Clinical Practice Oncology 6:3, 143-152
CrossRef571
Sonja Loges, Massimiliano Mazzone, Philipp Hohensinner, Peter Carmeliet. (2009) Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited. Cancer Cell 15:3, 167-170
CrossRef572
Nirit Yarom, Arnoldo Cyjon, Svetlana Kovel, Adelya Yachnin, Avishay Sella, Ella Evron. (2009) Epistaxis during Treatment with Paclitaxel. Basic & Clinical Pharmacology & Toxicology 104:3, 259-261
CrossRef573
Yago Nieto, Elizabeth J Shpall. (2009) High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?. Current Opinion in Oncology 21:2, 150-157
CrossRef574
H. Chen, R. A. Campbell, Y. Chang, M. Li, C. S. Wang, J. Li, E. Sanchez, M. Share, J. Steinberg, A. Berenson, D. Shalitin, Z. Zeng, D. Gui, P. Perez-Pinera, R. J. Berenson, J. Said, B. Bonavida, T. F. Deuel, J. R. Berenson. (2009) Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis. Blood 113:9, 1992-2002
CrossRef575
Thomas W. Flaig, Fernando J. Kim, Francisco G. Rosa, Kathryn Breaker, Jonathan Schoen, Paul D. Russ. (2009) Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Investigational New Drugs 27:1, 83-87
CrossRef576
F. O. Ademuyiwa, G. W. Sledge. (2009) Anti-angiogenic therapy: from laboratory to the patient. Breast Cancer Online 12:02,
CrossRef577
J. Robert Newman, Emily E. Helman, Seena Safavy, Wenyue Zhang, Eben L. Rosenthal. (2009) EMMPRIN expression is required for response to bevacizumab therapy in HNSCC xenografts. Cancer Letters 274:2, 313-318
CrossRef578
Patrick G Morris, Monica N Fornier. (2009) Novel anti-tubulin cytotoxic agents for breast cancer. Expert Review of Anticancer Therapy 9:2, 175-185
CrossRef579
G C Kumaran, G C Jayson, A R Clamp. (2009) Antiangiogenic drugs in ovarian cancer. British Journal of Cancer 100:1, 1-7
CrossRef580
Katherine H. Rak Tkaczuk. (2009) Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clinical Therapeutics 31, 2273-2289
CrossRef581
Arlene Chan. (2009) Antiangiogenic Therapy for Metastatic Breast Cancer. Drugs 69:2, 167-181
CrossRef582
M. Arroyo Yustos, R. Molina Villaverde, J.L. López González, M. Álvarez-Mon Soto. (2009) Cáncer de mama (II). Tratamiento sistémico. Medicine - Programa de Formación Médica Continuada Acreditado 10:24, 1583-1590
CrossRef583
Maurie Markman. (2009) Progression-free survival versus overall survival as the primary end point in anticancer drug trials: Increasingly relevant impact of therapy following progression. Current Oncology Reports 11:1, 1-2
CrossRef584
Yongping Crawford, Napoleone Ferrara. (2009) VEGF inhibition: insights from preclinical and clinical studies. Cell and Tissue Research 335:1, 261-269
CrossRef585
2009. BIBLIOGRAPHIE. , 176-189.
CrossRef586
Yeon Hee Park. (2009) Drug Therapy for Breast Cancer. Journal of the Korean Medical Association 52:10, 963
CrossRef587
Woo-Chan Park, Lee Su Kim, Tae Hyun Kim, Byeong-Woo Park, Ho Yong Park, Byung Joo Song, Jae Bok Lee, Chang Wan Jeon, Un-Jong Choi. (2009) Molecular Targets for Treatment of Breast Cancer. Journal of Breast Cancer 12:4, 229
CrossRef588
D. Mauri, N. P. Polyzos, G. Salanti, N. Pavlidis, J. P. A. Ioannidis. (2008) Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer. JNCI Journal of the National Cancer Institute 100:24, 1780-1791
CrossRef589
Francis Y. F. Lee, Robert Borzilleri, Craig R. Fairchild, Amrita Kamath, Richard Smykla, Robert Kramer, Gregory Vite. (2008) Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemotherapy and Pharmacology 63:1, 157-166
CrossRef590
Iyad N Daher, Edward TH Yeh. (2008) Vascular complications of selected cancer therapies. Nature Clinical Practice Cardiovascular Medicine 5:12, 797-805
CrossRef591
William J. Irvin, Lisa A. Carey. (2008) What is triple-negative breast cancer?. European Journal of Cancer 44:18, 2799-2805
CrossRef592
Joseph Gligorov, Jean-Pierre Lotz. (2008) Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment 112:S1, 53-66
CrossRef593
Serena Di Cosimo, José Baselga. (2008) Targeted therapies in breast cancer: Where are we now?. European Journal of Cancer 44:18, 2781-2790
CrossRef594
Louis WC CHOW, Young-Hyuck IM. (2008) Current treatment of locally advanced and metastatic breast cancer in the Asia-Pacific region: Challenges and limitations. Asia-Pacific Journal of Clinical Oncology 4, S14-S23
CrossRef595
Marianna Aita, Gianpiero Fasola, Carlotta Defferrari, Annalisa Brianti, Maria Giovanna Dal Bello, Alessandro Follador, Graziella Sinaccio, Paolo Pronzato, Francesco Grossi. (2008) Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer. Critical Reviews in Oncology/Hematology 68:3, 183-196
CrossRef596
C. C. Zielinski. (2008) Treatment of metastatic breast cancer: a historical perspective. memo - Magazine of European Medical Oncology 1:4, 227-234
CrossRef597
Yanelys Morera, Mónica Bequet-Romero, Marta Ayala, Humberto Lamdán, Else-Marie Agger, Peter Andersen, Jorge V. Gavilondo. (2008) Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants. Angiogenesis 11:4, 381-393
CrossRef598
Nancy U. Lin, Elizabeth Claus, Jessica Sohl, Abdul R. Razzak, Amal Arnaout, Eric P. Winer. (2008) Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer. Cancer 113:10, 2638-2645
CrossRef599
T J Price, L Lipton, J McGreivy, S McCoy, Y-N Sun, M A Rosenthal. (2008) Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours. British Journal of Cancer 99:9, 1387-1394
CrossRef600
R Torrisi, V Bagnardi, A Cardillo, F Bertolini, E Scarano, L Orlando, P Mancuso, A Luini, A Calleri, G Viale, A Goldhirsch, M Colleoni. (2008) Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. British Journal of Cancer 99:10, 1564-1571
CrossRef601
Ferry ALM Eskens, Stefan Sleijfer. (2008) The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: Where does it fit?. European Journal of Cancer 44:16, 2350-2356
CrossRef602
Devalingam Mahalingam, Francis Giles. (2008) Challenges in developing targeted therapy for pancreatic adenocarcinoma. Expert Opinion on Therapeutic Targets 12:11, 1389-1401
CrossRef603
Antoinette R. Tan, Sandra M. Swain. (2008) Therapeutic Strategies for Triple-Negative Breast Cancer. The Cancer Journal 14:6, 343-351
CrossRef604
Giuseppe Aprile, Ornella Belvedere, Fabio Puglisi. (2008) From the podium to the patient: bringing the 2008 ASCO meeting to the clinic. Anti-Cancer Drugs 19:10, 941-956
CrossRef605
Federico Rojo, Joan Albanell, Ana Rovira, Josep Maria Corominas, Felix Manzarbeitia. (2008) Targeted therapies in breast cancer. Seminars in Diagnostic Pathology 25:4, 245-261
CrossRef606
V. Roy, B. R. LaPlant, G. G. Gross, C. L. Bane, F. M. Palmieri, . (2008) Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane(R)) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Annals of Oncology 20:3, 449-453
CrossRef607
E. D. Saad, A. Katz. (2008) Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined. Annals of Oncology 20:3, 460-464
CrossRef608
T. Liakakos, E. Fatourou, D. Ziogas, E. Lykoudis, Dimitrios H. Roukos. (2008) Targeting VEGF, EGFR, and Other Interacting Pathways for Gastric Cancer—Promises and Reality. Annals of Surgical Oncology 15:10, 2981-2982
CrossRef609
Bernard Escudier, Jan Cosaert, Pavel Pisa. (2008) Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma. Expert Review of Anticancer Therapy 8:10, 1545-1557
CrossRef610
D. Pereg, M. Lishner. (2008) Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword?. European Heart Journal 29:19, 2325-2326
CrossRef611
Giulio Metro, Marcella Mottolese, Alessandra Fabi. (2008) HER-2-positive metastatic breast cancer: trastuzumab and beyond. Expert Opinion on Pharmacotherapy 9:15, 2583-2601
CrossRef612
PJ Wysocki, H Wysocki. (2008) Cardiovascular complications associated with biological therapies for breast cancer. Expert Opinion on Biological Therapy 8:10, 1551-1559
CrossRef613
Grace K. Dy, Alex A. Adjei. (2008) Systemic cancer therapy: Evolution over the last 60 years. Cancer 113:S7, 1857-1887
CrossRef614
Paul Wheatley-Price, Frances A. Shepherd. (2008) Targeting Angiogenesis in the Treatment of Lung Cancer. Journal of Thoracic Oncology 3:10, 1173-1184
CrossRef615
Rebecca A. Miksad, Vera Zietemann, Raffaella Gothe, Ruth Schwarzer, Annette Conrads-Frank, Petra Schnell-Inderst, Björn Stollenwerk, Uwe Siebert. (2008) Progression-free survival as a surrogate endpoint in advanced breast cancer. International Journal of Technology Assessment in Health Care 24:04,
CrossRef616
Josep M. Llovet, Jordi Bruix. (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:4, 1312-1327
CrossRef617
Emmanouel Saloustros, Dimitris Mavroudis, Vassilis Georgoulias. (2008) Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opinion on Pharmacotherapy 9:15, 2603-2616
CrossRef618
Gennaro Daniele, Roberta Marciano, Giampaolo Tortora. (2008) The role of bevacizumab in breast cancer. European Journal of Cancer Supplements 6:14, 26-29
CrossRef619
Bhawna Sirohi, Katy Smith. (2008) Bevacizumab in the treatment of breast cancer. Expert Review of Anticancer Therapy 8:10, 1559-1568
CrossRef620
Josep Maria del Campo, Aleix Prat, Antonio Gil-Moreno, José Pérez, Marta Parera. (2008) Update on novel therapeutic agents for cervical cancer. Gynecologic Oncology 110:3, S72-S76
CrossRef621
K. Prassl, A. Sahanic, B. Reicher, H. Denz, M. Freund, M. Fiegl. (2008) Striking response with bevacizumab and chemotherapy in a woman with heavily pretreated breast cancer: a case presentation. memo - Magazine of European Medical Oncology 1:3, 149-151
CrossRef622
Kai-Keen Shiu, David SP Tan, Jorge S Reis-Filho. (2008) Development of therapeutic approaches to ‘triple negative’ phenotype breast cancer. Expert Opinion on Therapeutic Targets 12:9, 1123-1137
CrossRef623
Dimitrios H Roukos. (2008) Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Review of Molecular Diagnostics 8:5, 587-597
CrossRef624
Yuval Shaked, Erik Henke, Jeanine M.L. Roodhart, Patrizia Mancuso, Marlies H.G. Langenberg, Marco Colleoni, Laura G. Daenen, Shan Man, Ping Xu, Urban Emmenegger, Terence Tang, Zhenping Zhu, Larry Witte, Robert M. Strieter, Francesco Bertolini, Emile E. Voest, Robert Benezra, Robert S. Kerbel. (2008) Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents. Cancer Cell 14:3, 263-273
CrossRef625
Yesim Gokmen-Polar, Kathy D. Miller. (2008) Redefining the Target Again: Chemotherapeutics as Vascular Disrupting Agents?. Cancer Cell 14:3, 195-196
CrossRef626
E.J. Kantelhardt, R. Große, H.G. Strauß, C. Thomssen. (2008) Mammakarzinom – State of the Art 2008. Der Gynäkologe 41:9, 672-682
CrossRef627
Gabriele Bergers, Douglas Hanahan. (2008) Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer 8:8, 592-603
CrossRef628
U. Ayazpoor. (2008) Fortbildung in der gynäkologischen Onkologie. Der Gynäkologe 41:8, 628-631
CrossRef629
Francesco Atzori, Monica Fornier. (2008) Epothilones in breast cancer: current status and future directions. Expert Review of Anticancer Therapy 8:8, 1299-1311
CrossRef630
B. Melichar, P. Koralewski, A. Ravaud, A. Pluzanska, S. Bracarda, C. Szczylik, C. Chevreau, M. Filipek, R. Delva, E. Sevin, S. Negrier, J. McKendrick, A. Santoro, P. Pisa, B. Escudier. (2008) First-line bevacizumab combined with reduced dose interferon- 2a is active in patients with metastatic renal cell carcinoma. Annals of Oncology 19:8, 1470-1476
CrossRef631
Michael Boyiadzis, Kenneth A Foon. (2008) Approved monoclonal antibodies for cancer therapy. Expert Opinion on Biological Therapy 8:8, 1151-1158
CrossRef632
Farbod Shojaei, Cuiling Zhong, Xiumin Wu, Lanlan Yu, Napoleone Ferrara. (2008) Role of myeloid cells in tumor angiogenesis and growth. Trends in Cell Biology 18:8, 372-378
CrossRef633
Lee M. Ellis, Daniel J. Hicklin. (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Reviews Cancer 8:8, 579-591
CrossRef634
Debu Tripathy. (2008) Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology; Chicago, IL; May 30-June 3, 2008. Clinical Breast Cancer 8:4, 313-321
CrossRef635
Lee, Thomas H., Emanuel, Ezekiel J., . (2008) Tier 4 Drugs and the Fraying of the Social Compact. New England Journal of Medicine 359:4, 333-335
Full Text636
Axel Grothey, Dirk Arnold, Lee M. Ellis. (2008) Should bevacizumab be continued beyond progression in colorectal cancer?. Current Colorectal Cancer Reports 4:3, 139-143
CrossRef637
H NIMEIRI, A OZA, R MORGAN, G FRIBERG, K KASZA, L FAORO, R SALGIA, W STADLER, E VOKES, G FLEMING. (2008) Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia
. Gynecologic Oncology 110:1, 49-55
CrossRef638
Barrett W. Newsome, Marc S. Ernstoff. (2008) The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?. British Journal of Clinical Pharmacology 66:1, 6-19
CrossRef639
G. Philippin-Lauridant, S. Thureau, M.-J. Ouvrier, E. Blot. (2008) Fatal hemoptysis in a patient with breast cancer treated with bevacizumab and paclitaxel. Annals of Oncology 19:11, 1977-1978
CrossRef640
Robert J. Gray. 2008. Eastern Cooperative Oncology Group (ECOG). .
CrossRef641
S. Seeber, A. Welt. (2008) Das metastasierte Mammakarzinom. best practice onkologie 3:3, 4-16
CrossRef642
Helen M. Coley. (2008) Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treatment Reviews 34:4, 378-390
CrossRef643
A Brunello, A Jirillo, C Falci, S Lonardi, U Basso, S Monfardini. (2008) Treatment of advanced breast cancer in elderly women: medical approach. Aging Health 4:3, 267-277
CrossRef644
Michel Marty, Xavier Pivot. (2008) The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumab. European Journal of Cancer 44:7, 912-920
CrossRef645
Axel Grothey, Lee M. Ellis. (2008) Targeting Angiogenesis Driven by Vascular Endothelial Growth Factors Using Antibody-Based Therapies. The Cancer Journal 14:3, 170-177
CrossRef646
Li Yan, Karl Hsu, Robert A. Beckman. (2008) Antibody-Based Therapy for Solid Tumors. The Cancer Journal 14:3, 178-183
CrossRef647
F. J. Esteva, G. N. Hortobagyi. (2008) Can Early Response Assessment Guide Neoadjuvant Chemotherapy in Early-Stage Breast Cancer?. JNCI Journal of the National Cancer Institute 100:8, 521-523
CrossRef648
(2008) Paclitaxel plus Bevacizumab for Metastatic Breast Cancer. New England Journal of Medicine 358:15, 1637-1638
Full Text649
Constantin N Baxevanis. (2008) Antibody-based cancer therapy. Expert Opinion on Drug Discovery 3:4, 441-452
CrossRef650
Volker Heinemann. (2008) Review of bevacizumab in the treatment of metastatic breast cancer. European Journal of Cancer Supplements 6:8, 13-18
CrossRef651
Edith M. Marom, Carlos H. Martinez, Mylene T. Truong, Xiudong Lei, Bradley S. Sabloff, Reginald F. Munden, Gregory W. Gladish, Roy S. Herbst, Rodolfo C. Morice, David J. Stewart, Carlos A. Jimenez, George R. Blumenschein, Amir Onn. (2008) Tumor Cavitation During Therapy with Antiangiogenesis Agents in Patients with Lung Cancer. Journal of Thoracic Oncology 3:4, 351-357
CrossRef652
(2008) News in Brief. Nature Reviews Drug Discovery 7:4, 280-281
CrossRef653
Joachim Drevs. (2008) VEGF and angiogenesis: implications for breast cancer therapy. European Journal of Cancer Supplements 6:6, 7-13
CrossRef654
David Cameron. (2008) Bevacizumab in the first-line treatment of metastatic breast cancer. European Journal of Cancer Supplements 6:6, 21-28
CrossRef655
David Miles. (2008) Management of toxicity in patients receiving therapy with bevacizumab. European Journal of Cancer Supplements 6:6, 29-39
CrossRef656
Richard Bell, David Cameron. (2008) Bevacizumab: the first anti-angiogenic agent approved for the treatment of metastatic breast cancer. European Journal of Cancer Supplements 6:6, 1-6
CrossRef657
Nadia Harbeck. (2008) Clinical data for anti-angiogenic agents in previously treated advanced breast cancer. European Journal of Cancer Supplements 6:6, 14-20
CrossRef658
Jacyntha A. Sterling. (2008) Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy. Hospital Pharmacy 43:3, 238-242
CrossRef659
David Cameron, Richard Bell. (2008) Future use of bevacizumab and other anti-angiogenic agents in breast cancer. European Journal of Cancer Supplements 6:6, 40-50
CrossRef660
E.L. Mayer. (2008) Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer. Breast Diseases: A Year Book Quarterly 19:3, 272-273
CrossRef661
Francesco Di Costanzo, Francesca Mazzoni, Marinella Micol Mela, Lorenzo Antonuzzo, Daniele Checcacci, Matilde Saggese, Federica Di Costanzo. (2008) Bevacizumab in Non-Small Cell Lung Cancer. Drugs 68:6, 737-746
CrossRef662
Gwo-Che Huang, Lee-Jen Chen, Hung-Chang Liu, Yu-Jen Chen. (2008) Development of Vitreous Haemorrhage during Treatment with Bevacizumab for Metastatic Rectal Cancer. Clinical Drug Investigation 28:8, 523-526
CrossRef
- Letters
